Investor Relations

Press Releases

Date Title/Summary View
Toggle Summary Vericel Added to Russell 3000® Index
CAMBRIDGE, Mass. , June 25, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it has been added to the Russell 3000 ® Index as part of the annual Russell U.S.
View HTML
Toggle Summary Vericel Corporation Announces Closing of $74.8 Million Public Offering and Full Exercise of The Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass. , June 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common
View HTML
Toggle Summary Vericel Corporation Prices $65 Million Public Offering of Common Stock
CAMBRIDGE, Mass. , May 31, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common
View HTML
Toggle Summary Vericel Corporation Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. , May 30, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it intends to offer and sell, subject to market and other conditions, 3,750,000 shares of its common
View HTML
Toggle Summary Vericel to Present at the Jefferies 2018 Global Healthcare Conference
CAMBRIDGE, Mass. , May 25, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the Jefferies 2018
View HTML
Toggle Summary Vericel Reports First Quarter 2018 Financial Results
Record First Quarter Revenues of $18.0 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass. , May 08, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial
View HTML
Toggle Summary Vericel to Report First-Quarter 2018 Financial Results on May 8, 2018
CAMBRIDGE, Mass. , April 24, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2018 financial results and
View HTML
Toggle Summary Vericel to Present at the 6th Annual Cell & Gene Therapy Investor Day
CAMBRIDGE, Mass. , April 10, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 6 th Annual
View HTML
Toggle Summary Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years
CAMBRIDGE, Mass. , March 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of results from the MACI ® (autologous cultured chondrocytes on porcine collagen
View HTML
Toggle Summary Vericel to Present at the 17th Annual Needham Healthcare Conference
CAMBRIDGE, Mass. , March 13, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 17 th Annual
View HTML
Toggle Summary Vericel to Host Analyst and Investor Day on April 11, 2018
CAMBRIDGE, Mass. , March 12, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it will host an Analyst and Investor Day on April 11, 2018 in New York City from 8:30 a.m.
View HTML
Toggle Summary Vericel to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference
CAMBRIDGE, Mass. , March 09, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel , chief financial officer and VP of corporate development, will present the latest
View HTML
Toggle Summary Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance
Record Quarterly Revenues of $23.4 Million Represent a 41% Increase Over Fourth Quarter 2016 Positive Operating and Net Income Reported for the Fourth Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a
View HTML
Toggle Summary World Champion Swimmer and Twelve-Time Medalist Dara Torres Partners with Vericel for the ‘It’s Your Move’ Campaign
Campaign Aims to Empower Patients with Knee Pain to Seek Treatment CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that world champion swimmer,
View HTML
Toggle Summary Vericel to Present at the 13th Annual Canaccord Genuity Musculoskeletal Conference
CAMBRIDGE, Mass. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 13th Annual
View HTML
Toggle Summary Vericel to Report Fourth-Quarter and Full-Year 2017 Financial Results on March 5, 2018
CAMBRIDGE, Mass. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter and full-year 2017 financial
View HTML
Toggle Summary Vericel to Present at the BIO CEO & Investor Conference
CAMBRIDGE, Mass. , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the BIO CEO &
View HTML
Toggle Summary Vericel to Present at the 7th Annual Leerink Partners Global Healthcare Conference
CAMBRIDGE, Mass. , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 7 th Annual
View HTML
Toggle Summary Vericel to Present at the 20th Annual Needham Growth Conference
CAMBRIDGE, Mass. , Jan. 10, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo , president and CEO, will present the latest
View HTML
Toggle Summary Vericel Initiates Collaboration with Innovative Cellular Therapeutics
CAMBRIDGE, Mass. and SHANGHAI, China, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the initiation of its License Agreement with
View HTML
Toggle Summary Vericel Enters into Expanded $25 Million Debt Facilities with Silicon Valley Bank and MidCap Financial to Support Accelerating MACI Uptake and Increased Epicel Usage
Facilities Include a $15 Million Term Loan and $10 Million Revolving Line of Credit CAMBRIDGE, Mass. , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions,
View HTML
Toggle Summary Vericel to Present at 29th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass. , Nov. 16, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo , president and CEO, will present the latest
View HTML
Toggle Summary Vericel Reports Third-Quarter 2017 Financial Results
Record Third Quarter Revenue of $14.3 Million Represents a 30% Increase Over Third Quarter 2016   Results Driven by Continued Momentum of MACI Uptake and Expanded Epicel Usage   Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) --  Vericel Corporation
View HTML
Toggle Summary Vericel to Host Third-Quarter 2017 Earnings Webcast and Conference Call on November 7, 2017
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What: Vericel Corporation
View HTML
Toggle Summary Vericel Provides Business Updates at 2017 Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today provided a general business update during a previously announced webcast
View HTML
Toggle Summary Vericel to Present at the 2017 Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the Cell &
View HTML
Toggle Summary Vericel to Present at the Ladenburg Thalmann 2017 Healthcare Conference
CAMBRIDGE, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present the latest
View HTML
Toggle Summary Vericel Reports Second-Quarter 2017 Financial Results
Revenue of $17.0 Million Represents a 32% Increase Over Second Quarter 2016 Results Driven by Momentum of MACI Uptake Following Launch   Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of
View HTML
Toggle Summary Vericel to Host Second-Quarter 2017 Earnings Webcast and Conference Call on August 9, 2017
CAMBRIDGE, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call:     What: Vericel
View HTML
Toggle Summary Vericel to Host Symposium on MACI Implant for Treating Articular Cartilage Defects in the Knee at AOSSM 2017 Annual Meeting
CAMBRIDGE, Mass., July 13, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, announced today that the company is hosting a symposium on the  MACI ® (autologous
View HTML
Toggle Summary Vericel Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Ixmyelocel-T for the Treatment of Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
Ixmyelocel-T is the First Therapy to Receive the RMAT Designation for the Treatment of a Serious Cardiovascular Disease
View HTML
Toggle Summary Vericel Licenses Product Portfolio to Innovative Cellular Therapeutics for Distribution in China, South Korea, and other Countries in Southeast Asia
CAMBRIDGE, Mass. and SHANGHAI, China, May 10, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that it has entered into a License Agreement with
View HTML
Toggle Summary Vericel Reports First-Quarter 2017 Financial Results
Conference Call Today at 8:00am Eastern Time
View HTML
Toggle Summary Vericel to Host First-Quarter 2017 Earnings Webcast and Conference Call on May 10, 2017
CAMBRIDGE, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What:         Vericel
View HTML
Toggle Summary Vericel to Present at the 5th Annual Cell & Gene Therapy Investor Day
CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the 5th
View HTML
Toggle Summary Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs
Accomplished Industry Veteran Brings Extensive Quality and Regulatory Affairs Experience in Cell and Gene Therapies and Medical Devices
View HTML
Toggle Summary Vericel to Present at the 16th Annual Needham Healthcare Conference
CAMBRIDGE, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the 16 th
View HTML
Toggle Summary Outcomes Data From Over 950 Severe Burn Patients Treated With Epicel Presented at the 49th Annual Meeting of the American Burn Association
CAMBRIDGE, Mass., March 23, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the presentation of Epicel ® (cultured epidermal autografts [CEA])
View HTML
Toggle Summary Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results
Record Revenues of $16.5 Million Reported for the Fourth Quarter Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious
View HTML
Toggle Summary Vericel to Host Fourth-Quarter 2016 Earnings Webcast and Conference Call on March 10, 2017
CAMBRIDGE, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What:  Vericel Corporation
View HTML
Toggle Summary Vericel to Present at Multiple Upcoming Investor Conferences
  CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the
View HTML
Toggle Summary Vericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
CAMBRIDGE, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has designated the
View HTML
Toggle Summary Vericel Announces First MACI Implant in the United States for the Treatment of Symptomatic Cartilage Defects of the Knee
CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the first implant of MACI ® (autologous cultured chondrocytes on
View HTML
Toggle Summary Vericel Corporation Announces Exercise of Underwriters' Over-Allotment Option and Closing of $20 Million Offering of Common Stock
  CAMBRIDGE, Mass., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation ( VCEL ), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that it has closed its previously announced underwritten public offering
View HTML
Toggle Summary Vericel Corporation Prices $17 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the pricing of its previously announced underwritten public offering
View HTML
Toggle Summary Vericel Corporation Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that it intends to offer and sell shares of its common stock in an
View HTML
Toggle Summary FDA Approves MACI for the Treatment of Symptomatic Cartilage Defects of the Knee in Adults
First Tissue-Engineered Autologous Cellularized Scaffold Product Approved by the FDA Conference Call Today at 9:00am Eastern Standard Time CAMBRIDGE, Mass., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the
View HTML
Toggle Summary Vericel to Present at 28th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the
View HTML
Toggle Summary Additional Pre-Specified Secondary Results on the Reduction of Ventricular Arrhythmias Presented at AHA from Vericel's Positive Phase 2b ixCELL‑DCM Clinical Trial of Ixmyelocel-T
CAMBRIDGE, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, today announced the presentation of additional pre‑specified secondary endpoint results from the
View HTML
Toggle Summary Vericel Reports Third-Quarter 2016 Financial Results
Total Revenues of $10.9 Million Reported for the Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of severe diseases and conditions,
View HTML
Toggle Summary Vericel to Host Third-Quarter 2016 Earnings Webcast and Conference Call on November 7, 2016
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What:  Vericel Corporation
View HTML
Toggle Summary Vericel to Present at 2016 Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the annual Cell & Gene Meeting on
View HTML
Toggle Summary Vericel to Present at Ladenburg Thalmann Healthcare Conference
CAMBRIDGE, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Michel, chief financial officer and
View HTML
Toggle Summary Vericel Enters into Expanded $20 Million Credit Facility and Term Loan with Silicon Valley Bank and MidCap Financial Services
CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, announced today that it entered into an expanded term loan and revolving line of credit
View HTML
Toggle Summary Vericel to Present Data at the American Heart Association's Scientific Sessions 2016 on the Reduction of Ventricular Arrhythmias with Ixmyelocel-T in the ixCELL-DCM Clinical Trial
CAMBRIDGE, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, today announced the acceptance of an abstract for presentation at the American Heart
View HTML
Toggle Summary Vericel Reports Second-Quarter 2016 Financial Results
Total Revenues of $12.8 Million Reported for the Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of severe diseases and conditions,
View HTML
Toggle Summary Vericel to Host Second-Quarter 2016 Earnings Webcast and Conference Call on August 8, 2016
CAMBRIDGE, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call:     What:  Vericel Corporation
View HTML
Toggle Summary Vericel to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
CAMBRIDGE, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Michel, chief financial
View HTML
Toggle Summary Vericel Reports First-Quarter 2016 Financial Results
Total Revenues of $14.1 Million Reported for the Quarter Carticel and Epicel Revenues Increase 31% versus First Quarter 2015 Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., May 10, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific
View HTML
Toggle Summary Vericel to Host First-Quarter 2016 Earnings Webcast and Conference Call on May 10, 2016
CAMBRIDGE, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What: Vericel Corporation
View HTML
Toggle Summary Vericel to Present at 15th Annual Needham Healthcare Conference
CAMBRIDGE, Mass., April 08, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the 15th Annual
View HTML
Toggle Summary Results from Vericel's Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented Today at ACC and Published in The Lancet
Patients Treated with Ixmyelocel-T had a 37 Percent Reduction in Clinical Events Compared to Placebo
View HTML
Toggle Summary Vericel to Host Review of Positive Phase 2b ixCELL-DCM Trial Results Following American College of Cardiology 65th Annual Scientific Sessions
Key Opinion Leader to present full data results on April 5th in New York
View HTML
Toggle Summary Vericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy
CAMBRIDGE, Mass., March 28, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the publication of the clinical trial rationale and study design for the
View HTML
Toggle Summary Vericel Reports Fourth-Quarter and Year-End 2015 Financial Results
Total Revenues of $15.4 Million Reported for the Fourth Quarter Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe
View HTML
Toggle Summary Vericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy
Study Meets Primary Endpoint of Reduction in Clinical Cardiac Events
View HTML
Toggle Summary Vericel Enters Into $10 Million Credit Facility and $5 Million Term Loan Agreement With Silicon Valley Bank
CAMBRIDGE, Mass., March 09, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, announced today that it has entered into a term loan and revolving line of credit
View HTML
Toggle Summary Vericel to Present at 28th Annual ROTH Conference
CAMBRIDGE, Mass., March 08, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Michel, chief financial
View HTML
Toggle Summary Vericel Announces FDA Acceptance for Filing of BLA for MACI for the Treatment of Symptomatic Cartilage Defects in the Knee
CAMBRIDGE, Mass., March 07, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that the U.S. Food and Drug Administration has accepted for filing its
View HTML
Toggle Summary Vericel to Host Fourth-Quarter 2015 Earnings Webcast and Conference Call on March 14, 2016
CAMBRIDGE, Mass., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What: Vericel Corporation
View HTML
Toggle Summary Vericel to Present at Canaccord Genuity Investor Conference
CAMBRIDGE, Mass., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present at the Canaccord Genuity Musculoskeletal Conference in
View HTML
Toggle Summary Vericel Announces FDA Approval of Epicel HDE Supplement
Revised Product Label Includes Indication for Use in Pediatric Patients and Now Specifies a Probable Benefit of Epicel Mainly Related to Patient Survival
View HTML
Toggle Summary Vericel Submits Biologics License Application to the FDA for MACI for the Treatment of Cartilage Defects in the Knee
CAMBRIDGE, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it has submitted a Biologics License Application (BLA) to the U.S.
View HTML
Toggle Summary Vericel Submits HDE Supplement to the FDA to Revise the Labeled Indications for Use and Add Pediatric Labeling for Epicel
CAMBRIDGE, Mass., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it has submitted a Humanitarian Device Exemption (HDE) supplement to
View HTML
Toggle Summary Vericel Reports Third-Quarter 2015 Financial Results
Total Revenues of $11.3 Million Reported for the Third Quarter Carticel and Epicel Revenues Increase 19% Compared to Third Quarter of 2014 Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of
View HTML
Toggle Summary Vericel to Host Third-Quarter 2015 Earnings Webcast and Conference Call on November 13, 2015
CAMBRIDGE, Mass., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What: Vericel Corporation
View HTML
Toggle Summary Vericel Announces Long-Term Supply Agreement with Matricel for Key Component of MACI™
Vericel Announces Long-Term Supply Agreement with Matricel for Key Component of MACI ™
View HTML
Toggle Summary Vericel to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present at the following investor conferences in late
View HTML
Toggle Summary Vericel Reports Second-Quarter 2015 Financial Results
Total Revenues of $13.6 Million Reported for the Second Quarter Carticel and Epicel Revenues Increase 31% Compared to Second Quarter 2014 Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of
View HTML
Toggle Summary Vericel to Host Second-Quarter 2015 Earnings Webcast and Conference Call on August 12, 2015
Vericel to Host Second-Quarter 2015 Earnings Webcast and Conference Call on August 12, 2015 CAMBRIDGE, Mass., July 29, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL ), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and
View HTML
Toggle Summary Vericel Announces Plan to Submit HDE Supplement to the FDA to Revise the Labeled Indications for Use and Add Pediatric Labeling for Epicel
CAMBRIDGE, Mass., July 14, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that following discussions with the U.S.
View HTML
Toggle Summary Vericel Announces Plan to Submit Biologics License Application to FDA by Year-End 2015 for MACI for the Treatment of Cartilage Defects in the Knee
CAMBRIDGE, Mass., June 10, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that following discussions with the U.S.
View HTML
Toggle Summary Vericel Reports First-Quarter 2015 Financial Results
Total Revenues of $10.8 Million Reported for the First Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases
View HTML
Toggle Summary Vericel to Host First-Quarter 2015 Earnings Webcast and Conference Call on May 14, 2015
CAMBRIDGE, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What: Vericel Corporation
View HTML
Toggle Summary Vericel to Present at Needham Healthcare Conference
CAMBRIDGE, Mass., April 8, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present a corporate update at the 14 th Annual Needham
View HTML
Toggle Summary Vericel Reports Three-Year Follow-Up Results From Phase 3 SUMMIT Extension Study of MACI(TM) Implant
Poster Presentation at AAOS Annual Meeting Shows Continued Benefit Over Microfracture Bone Marrow Stimulation Procedure
View HTML
Toggle Summary Vericel Reports Fourth-Quarter and Year-End 2014 Financial Results
Total Revenues of $14.7 Million Reported for the Fourth Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., March 23, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe
View HTML
Toggle Summary Vericel to Present at Canaccord Genuity and ARM Investor Conferences
CAMBRIDGE, Mass., March 18, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present at the following investor conferences later this
View HTML
Toggle Summary Vericel to Host Fourth-Quarter 2014 Earnings Call on March 23, 2015
CAMBRIDGE, Mass., March 12, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following conference call and webcast: What: Vericel, Inc., Fourth
View HTML
Toggle Summary Vericel to Present at 27th Annual ROTH Conference
CAMBRIDGE, Mass., March 6, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Michel, chief financial
View HTML
Toggle Summary Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T
CAMBRIDGE, Mass., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the completion of patient enrollment in the company's Phase 2b ixCELL-DCM
View HTML
Toggle Summary Vericel Corporation Names Three New Board Members
Vericel Corporation Names Three New Board Members CAMBRIDGE, Mass., JANUARY 7, 2015 (GLOBE NEWSWIRE) - Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the appointment of
View HTML
Toggle Summary Aastrom Biosciences Changes Name to Vericel Corporation
Headquarters moved to Cambridge, Mass.; New ticker symbol: VCEL
View HTML
Toggle Summary Aastrom Biosciences Reports Third-Quarter 2014 Financial Results
Conference Call Today at 8:30 a.m. Eastern Time
View HTML
Toggle Summary Aastrom Biosciences to Host Third Quarter 2014 Earnings Call on November 13, 2014
ANN ARBOR, Mich., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast: What: Aastrom Biosciences, Inc., Third
View HTML
Toggle Summary Aastrom Biosciences Announces Plans to Change Name to Vericel Corporation and Move Headquarters to Cambridge, Massachusetts
ANN ARBOR, Mich., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced plans to change its corporate name to Vericel Corporation and move its
View HTML
Toggle Summary Aastrom Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
ANN ARBOR, Mich., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the closing of its previously announced underwritten public offering
View HTML
Toggle Summary Aastrom Biosciences to Present Three-Year Data From the SUMMIT Extension Study of MACI(TM) at the 2015 American Academy of Orthopedic Surgeons Annual Meeting
ANN ARBOR, Mich., Sept. 16, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that three-year results from the SUMMIT extension study on the
View HTML
Toggle Summary Aastrom Biosciences Announces Pricing of Public Offering of Common Stock
ANN ARBOR, Mich., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it has priced a public offering of 13,725,490 shares of its
View HTML
Toggle Summary Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy
Results From Phase 2a IMPACT-DCM and Catheter-DCM Studies Published in Circulation Research
View HTML
Toggle Summary Aastrom Biosciences Reports Second Quarter 2014 Financial Results
U.S. Commercial Business Generates Positive Contribution Conference Call Today at 8:30 a.m. Eastern Time ANN ARBOR, Mich., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific, expanded cellular therapies for the treatment of severe
View HTML
Toggle Summary Aastrom Biosciences to Host Second Quarter 2014 Earnings Call on August 14, 2014
ANN ARBOR, Mich., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast: What: Aastrom Biosciences, Inc., Second
View HTML
Toggle Summary Aastrom Announces Appointment of Zac Taylor as National Sales Director
Experienced Senior Sales Professional Brings Wealth of Marketing, Strategic Planning and Brand Management Expertise to Aastrom
View HTML
Toggle Summary Aastrom Biosciences Added to Russell Microcap Index
ANN ARBOR, Mich., June 30, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will be included in the Russell Microcap ® Index, according
View HTML
Toggle Summary Aastrom Announces Initiation of Commercial Sales of Bone Marrow by Marrow Donation, LLC
ANN ARBOR, Mich., June 24, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the initiation of commercial sales of bone marrow by Marrow
View HTML
Toggle Summary Aastrom Announces Strategic Plan for Recently Acquired Cell Therapy and Regenerative Medicine Business
Manufacturing of MACI in Denmark to be discontinued Sales of MACI in Europe, representing 1% of revenues in 2014, temporarily ceased U.S. action plan implemented to optimize R&D, manufacturing and commercial operations Measures expected to enable company to generate positive cash flow from the U.S.
View HTML
Toggle Summary Aastrom Announces Investor Conference Call and Webcast June 16, 2014 at 8:30 AM EDT
ANN ARBOR, Mich., June 15, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, will hold an investor conference call and slide presentation on Monday, June 16,
View HTML
Toggle Summary Aastrom Announces Appointment of Gerard Michel as Chief Financial Officer and Vice President, Corporate Development
Accomplished Industry Veteran Brings Extensive History of Successful Corporate Development, Fundraising and Capital Management to Aastrom
View HTML
Toggle Summary Aastrom Completes Acquisition of Sanofi's Cell Therapy and Regenerative Medicine Business
ANN ARBOR, Mich., June 2, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that the company has completed its acquisition of Sanofi's cell
View HTML
Toggle Summary Aastrom Biosciences Reports First-Quarter 2014 Financial Results
Conference Call May 15, 2014 at 4:30 PM Eastern Time
View HTML
Toggle Summary Aastrom Biosciences to Host First Quarter 2014 Investor Call on May 15, 2014
ANN ARBOR, Mich., May 9, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, announces the following webcast: What: Aastrom Biosciences, Inc., First
View HTML
Toggle Summary Aastrom to Hold Annual Meeting of Shareholders on May 7, 2014
ANN ARBOR, Mich., May 2, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that the company will hold its annual shareholders
View HTML
Toggle Summary Aastrom Announces Definitive Agreement to Acquire Sanofi's Cell Therapy and Regenerative Medicine Business
Acquisition of Landmark Autologous Cell Therapy Portfolio and Manufacturing Centers in U.S. and Europe Positions Aastrom as a Global Leader in Regenerative Medicine
View HTML
Toggle Summary Aastrom Reports Data and Safety Monitoring Board Recommendation to Continue ixCELL-DCM Clinical Trial
ANN ARBOR, Mich., April 9, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that the independent Data and Safety Monitoring
View HTML
Toggle Summary Aastrom Announces Appointments of Dr. Ross Tubo as Chief Scientific Officer and Dr. David Recker as Chief Medical Officer
Globally Recognized Industry Veterans Bring Extensive R&D and Product Development Experience in Regenerative Medicine and Multiple Therapeutic Areas
View HTML
Toggle Summary Aastrom Biosciences to Present at the 2014 Regen Med Investor Day
ANN ARBOR, Mich., March 19, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that Nick Colangelo, President and CEO of Aastrom,
View HTML
Toggle Summary Aastrom Biosciences Reports Fourth-Quarter and Year-End 2013 Financial Results
Conference Call March 13, 2014 at 4:30 PM Eastern Time
View HTML
Toggle Summary Aastrom Biosciences to Host Fourth Quarter 2013 Investor Call on March 13, 2014
ANN ARBOR, Mich., March 6, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, announces the following webcast: What: Aastrom Biosciences, Inc.,
View HTML
Toggle Summary Aastrom Biosciences Enters Into $15 Million Equity Commitment With Lincoln Park Capital
ANN ARBOR, Mich., Jan. 27, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that it has entered into a stock purchase agreement
View HTML
Toggle Summary Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia
ANN ARBOR, Mich., Dec. 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that it has been granted a key composition-of-matter
View HTML
Toggle Summary Aastrom Biosciences Regains Compliance With NASDAQ Equity Standard Listing Requirement
ANN ARBOR, Mich., Nov. 15, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that on November 14, 2013, the Company was notified
View HTML
Toggle Summary Aastrom Biosciences to Present at the 2013 Therapeutic Area Partnerships Conference
Ixmyelocel-T Named a "Top Project to Watch" in Advanced Therapies by Elsevier Business Intelligence
View HTML
Toggle Summary Aastrom Biosciences Reports Third-Quarter and Nine-Month 2013 Financial Results
Conference Call November 12, 2013 at 4:30 PM Eastern Time
View HTML
Toggle Summary Aastrom Biosciences to Host Third Quarter 2013 Investor Call on November 12, 2013
ANN ARBOR, Mich., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, announces the following webcast: What: Aastrom Biosciences, Inc., Third
View HTML
Toggle Summary Aastrom Announces Results of Two Studies of Ixmyelocel-T Published in Stem Cell Research & Therapy
Results Demonstrate Reparative Properties of Unique Macrophage Population Found in Ixmyelocel-T and Potential Role in Reverse Transport of Cholesterol
View HTML
Toggle Summary Aastrom Biosciences Regains Compliance With NASDAQ Minimum Bid Requirement
ANN ARBOR, Mich., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today reported that the company has regained compliance with the $1.00
View HTML
Toggle Summary Aastrom Biosciences One-for-Twenty Reverse Stock Split Now Effective
ANN ARBOR, Mich., Oct. 16, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today reported that its previously announced one-for-twenty reverse
View HTML
Toggle Summary Aastrom Biosciences to Present at the 2013 Stem Cell Meeting on the Mesa Conference
ANN ARBOR, Mich., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that Nick Colangelo, President and CEO of Aastrom,
View HTML
Toggle Summary Aastrom Biosciences Announces One-for-Twenty Reverse Stock Split
ANN ARBOR, Mich., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, announced today that its board of directors has approved a
View HTML
Toggle Summary Aastrom Biosciences to Present at the Aegis Capital 2013 Healthcare Conference
ANN ARBOR, Mich., Sept. 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that Nick Colangelo, President and CEO of Aastrom,
View HTML
Toggle Summary Aastrom Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada
ANN ARBOR, Mich., Sept. 16, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that Health Canada has approved the company's
View HTML
Toggle Summary Heidi Hagen Joins Aastrom Board of Directors
ANN ARBOR, Mich., Aug. 26, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that Heidi Hagen has joined the Aastrom Board of
View HTML
Toggle Summary Aastrom Biosciences, Inc. Announces Closing of Public Offering of Common Stock and Warrants
ANN ARBOR, Mich., Aug. 16, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today the closing of the previously announced underwritten
View HTML
Toggle Summary Aastrom Biosciences, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
ANN ARBOR, Mich., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that it has priced a public offering of 29,000,000
View HTML
Toggle Summary Aastrom Biosciences Announces Amendment of Series B Preferred Stock Certificate of Designations, Preferences and Rights
Amendment Increases Shareholders' Equity by $37.7 Million
View HTML
Toggle Summary Aastrom Biosciences Reports Second-Quarter and First-Half 2013 Financial Results
Conference Call August 15, 2013 at 4:30 PM Eastern Time
View HTML
Toggle Summary Aastrom Biosciences to Present at the JMP Securities Healthcare Conference
ANN ARBOR, Mich., July 3, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that Nick Colangelo, president and CEO of Aastrom, will
View HTML
Toggle Summary Aastrom Biosciences Reports First Quarter 2013 Financial Results
Conference Call Today at 4:30 PM Eastern Time
View HTML
Toggle Summary Aastrom to Host First Quarter 2013 Investor Call on May 8, 2013
ANN ARBOR, Mich., May 3, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the following webcast: What: Aastrom Biosciences, Inc.,
View HTML
Toggle Summary Aastrom to Hold Annual Meeting of Shareholders on May 2, 2013
ANN ARBOR, Mich., April 25, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that the company will hold its annual shareholders
View HTML
Toggle Summary Aastrom Biosciences Announces First Patients Treated in ixCELL-DCM Clinical Study of ixmyelocel-T
ANN ARBOR, Mich., April 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that the first patients were treated in the
View HTML
Toggle Summary Aastrom Biosciences to Present at Multiple Conferences in April
ANN ARBOR, Mich., April 9, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that the company will be presenting at the following
View HTML
Toggle Summary Aastrom Biosciences Announces First Patients Enrolled in ixCELL-DCM Phase 2b Clinical Trial of Ixmyelocel-T
ANN ARBOR, Mich., April 4, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that the first patients have been enrolled in the
View HTML
Toggle Summary Aastrom Biosciences Announces Strategic Change in Research and Development Programs to Focus on Dilated Cardiomyopathy and Other Rare Disease Indications
Focus shifted to Phase 2b ixCELL-DCM clinical study and the development of ixmyelocel-T for dilated cardiomyopathy, an orphan drug indication. Company to stop enrollment and end Phase 3 REVIVE CLI study following strategic program review. Corporate restructuring will significantly reduce operating
View HTML
Toggle Summary Aastrom Biosciences Reports Fourth-Quarter and Year-End 2012 Financial Results
Conference Call Today at 4:30 PM Eastern Time
View HTML
Toggle Summary Aastrom to Host Fourth Quarter 2012 Investor Call on March 18, 2013
ANN ARBOR, Mich., March 12, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the following webcast: What:   Aastrom Biosciences, Inc.,
View HTML
Toggle Summary Aastrom Board of Directors Names Dominick C. Colangelo President and Chief Executive Officer
ANN ARBOR, Mich., March 6, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that the company's board of directors has named
View HTML
Toggle Summary Aastrom Board of Directors Names Dan Orlando Interim CEO
ANN ARBOR, Mich., Dec. 12, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that the company's board of directors has named Dan
View HTML
Toggle Summary Aastrom to Present at the 23rd Annual Oppenheimer Healthcare Conference
ANN ARBOR, Mich., Dec. 10, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that Chief Commercial Officer Dan Orlando will
View HTML
Toggle Summary Aastrom Board Member Dr. Harold C. Urschel of Baylor University Medical Center Passes Away
ANN ARBOR, Mich., Nov. 26, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, is sad to announce that Harold C.
View HTML
Toggle Summary Aastrom to Present at Therapeutic Area Partnerships Meeting
ANN ARBOR, Mich., Nov. 20, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that Chief Commercial Officer Dan Orlando will
View HTML
Toggle Summary Aastrom Biosciences Reports Third-Quarter and Nine-Month 2012 Financial Results
Conference Call Today at 4:30 PM Eastern Time
View HTML
Toggle Summary Aastrom to Host Third Quarter 2012 Investor Call on November 8, 2012
ANN ARBOR, Mich., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the following webcast: What: Aastrom Biosciences, Inc.,
View HTML
Toggle Summary Aastrom Biosciences Announces Appointment of Joyce L. Frey-Vasconcells, Ph.D. to Scientific Advisory Board
ANN ARBOR, Mich., Oct. 29, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that cell therapy regulatory and development expert
View HTML
Toggle Summary Aastrom Biosciences CEO Tim M. Mayleben Announces Plan to Retire
Company Initiates CEO Succession Plan
View HTML
Toggle Summary Aastrom to Participate in Noble Financial Capital Markets' BioX Life Sciences Exposition
ANN ARBOR, Mich., Sept. 19, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will
View HTML
Toggle Summary Aastrom Biosciences Appoints Daniel R. Orlando as Chief Commercial Officer
ANN ARBOR, Mich., Sept. 5, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced the appointment of Daniel (Dan) R.
View HTML
Toggle Summary Aastrom Biosciences Reports Operating Results for the Quarter and Six Months Ended June 30, 2012
Conference Call Today at 4:30 PM Eastern Time
View HTML
Toggle Summary Aastrom to Host Second Quarter 2012 Investor Call on August 7, 2012
ANN ARBOR, Mich., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, will hold a second quarter investor call on Tuesday, August 7, 2012
View HTML
Toggle Summary Aastrom Announces Results of Common Stock Exchange for December 2010 Warrants
ANN ARBOR, Mich., July 30, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that it has completed the previously announced
View HTML
Toggle Summary Aastrom Announces Common Stock Exchange for December 2010 Warrants
ANN ARBOR, Mich., June 27, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that it plans to exchange for common stock up to
View HTML
Toggle Summary Ixmyelocel-T Shown to Protect Heart From Damage in Murine Model of Heart Failure
Data Showing Treatment With Ixmyelocel-T Resulted in Decreased Infarct Size Presented in Poster Presentation at the 18th Annual International Society for Cellular Therapy Meeting
View HTML
Toggle Summary Aastrom Biosciences to Present at World Stem Cells & Regenerative Medicine Congress
ANN ARBOR, Mich., May 17, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will be
View HTML
Toggle Summary Aastrom Biosciences Reports First Quarter 2012 Financial Results
Conference Call Today at 4:30 PM Eastern Time
View HTML
Toggle Summary Aastrom Biosciences Announces First Patient Enrolled in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T
ANN ARBOR, Mich., May 9, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that the first patient has been enrolled in the REVIVE
View HTML
Toggle Summary Aastrom to Present Results of Phase 2a Clinical Trial of Ixmyelocel-T in Dilated Cardiomyopathy Patients at SCAI Scientific Sessions
ANN ARBOR, Mich., May 7, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that results from the company's Phase 2a clinical
View HTML
Toggle Summary Webcast Alert: Aastrom to Host First Quarter 2012 Investor Call on May 10, 2012
ANN ARBOR, Mich., May 7, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the following webcast:     What:  Aastrom Biosciences, Inc.,
View HTML
Toggle Summary Aastrom to Hold Annual Meeting of Shareholders on May 3, 2012
ANN ARBOR, Mich., April 30, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that the company will hold their annual shareholders
View HTML
Toggle Summary Final Results from RESTORE-CLI Phase 2b Clinical Trial for Ixmyelocel-T in Treatment of Critical Limb Ischemia Published in the Peer-Reviewed Journal Molecular Therapy
Results Confirm Improvement in Time to Treatment Failure and no Major Safety Issues
View HTML
Toggle Summary Aastrom to Present at the Needham & Company 11th Annual Healthcare Conference
ANN ARBOR, Mich., March 28, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will
View HTML
Toggle Summary Aastrom Biosciences to Present New Findings on Atheroprotective Effects of Ixmyelocel-T at Keystone Symposia on Atherosclerosis
ANN ARBOR, Mich., March 26, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that results from a preclinical study demonstrating
View HTML
Toggle Summary Aastrom Biosciences Appoints Dr. LaVonne Lang as Head of Regulatory Affairs
ANN ARBOR, Mich., March 14, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced the appointment of Dr.
View HTML
Toggle Summary Aastrom to Present at 24th Annual ROTH Capital Conference
ANN ARBOR, Mich., March 12, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will
View HTML
Toggle Summary Aastrom Biosciences Reports Fourth Quarter and Year-End 2011 Financial Results
Conference Call Today at 4:30 PM Eastern Time
View HTML
Toggle Summary Aastrom Biosciences Completes $40 Million Financing
ANN ARBOR, Mich., March 9, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has completed a $40 million private
View HTML
Toggle Summary Webcast Alert: Aastrom to Report Fourth Quarter and Year-End 2011 Operating Results on Monday, March 12, 2012
ANN ARBOR, Mich., March 9, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the following webcast: What:  Aastrom Biosciences, Inc.,
View HTML
Toggle Summary Aastrom Biosciences Announces Initiation of Patient Enrollment in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T
ANN ARBOR, Mich., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, has begun patient enrollment in the REVIVE Phase 3 clinical trial to
View HTML
Toggle Summary Aastrom Biosciences to Present at Piper Jaffray 23rd Annual Health Care Conference in New York City
ANN ARBOR, Mich., Nov. 22, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will
View HTML
Toggle Summary Aastrom Reports Positive 12-Month Results from the RESTORE-CLI Phase 2 Clinical Trial for Ixmyelocel-T in Patients with Critical Limb Ischemia
Results Presented Today at the American Heart Association Scientific Sessions Show Ixmyelocel-T Met Primary Safety and Efficacy Endpoints in CLI Patients With No Revascularization Options
View HTML
Toggle Summary Aastrom Biosciences to Hold Research and Development Day Review for Investors on November 17, 2011
ANN ARBOR, Mich., Nov. 11, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, will hold a Research and Development Day for investors on November
View HTML
Toggle Summary Aastrom Biosciences Reports Third Quarter 2011 Financial Results
ANN ARBOR, Mich., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today reported financial results for the quarter and nine months ended
View HTML
Toggle Summary New York Academy of Sciences Symposium on Advances in Adult Stem Cell Therapy in Tissue Repair for Cardiovascular Diseases to Feature Aastrom Biosciences
Researchers to Review Recent Preclinical and Clinical Findings on Use of Cellular Therapies Derived From Bone Marrow Stem Cells to Treat Chronic Cardiovascular Disease
View HTML
Toggle Summary Final 12-Month Results From the Aastrom RESTORE-CLI Phase 2b Clinical Trial to be Presented at the American Heart Association Scientific Sessions 2011 on Monday, November 14, 2011
ANN ARBOR, Mich., Nov. 1, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced that final 12-month results from the RESTORE-CLI Phase 2b
View HTML
Toggle Summary Webcast Alert: Aastrom to Host Third Quarter 2011 Investor Call on Tuesday, November 8, 2011
ANN ARBOR, Mich., Oct. 31, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the following webcast: What:       Aastrom Biosciences,
View HTML
Toggle Summary Aastrom Appoints Brian Gibson as Vice President, Finance
ANN ARBOR, Mich., Oct. 13, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that Brian Gibson has been named vice president of
View HTML
Toggle Summary Aastrom Granted European Composition-of-Matter Patent for Ixmyelocel-T
ANN ARBOR, Mich., Oct. 3, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has been granted a key composition of matter
View HTML
Toggle Summary Aastrom to Present at the Sixth Annual JMP Securities Healthcare Conference
ANN ARBOR, Mich., Sept. 23, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will
View HTML
Toggle Summary Aastrom Announces Positive 12-Month Safety and Efficacy Data From IMPACT-DCM Phase 2 Clinical Trial for Ixmyelocel-T in Treatment of Dilated Cardiomyopathy
Results presented today at 15th Annual Heart Failure Society of America Scientific Meeting Aastrom also announces results of six-month interim analysis of DCM patients treated with ixmyelocel-T via catheter administration. ANN ARBOR, Mich., Sept. 19, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences,
View HTML
Toggle Summary Aastrom Chief Scientific Officer Ronnda Bartel, PhD, to Present at the Cell Therapy Commercialization Summit
ANN ARBOR, Mich., Sept. 16, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that Ronnda Bartel, PhD, the company's chief
View HTML
Toggle Summary Aastrom to Present 12-Month Data From the IMPACT-DCM Phase 2 Clinical Trial for Ixmyelocel-T in Treatment of Dilated Cardiomyopathy
Principal Investigator Amit Patel, MD, MS, to Present 12-Month Safety and Efficacy Data in a Poster Presentation at the Heart Failure Society of America Scientific Meeting on September 19, 2011
View HTML
Toggle Summary Aastrom to Present at the 13th Annual Rodman & Renshaw Healthcare Conference
ANN ARBOR, Mich., Sept. 8, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will
View HTML
Toggle Summary Aastrom to Present at the Stifel Nicolaus Healthcare Conference
ANN ARBOR, Mich., Sept. 1, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will
View HTML
Toggle Summary Aastrom Biosciences Reports Operating Results for the Quarter and Six Months Ended June 30, 2011
Phase 3 REVIVE-CLI clinical trial to begin next quarter Final Phase 2b CLI data presentation at AHA meeting in November Final Phase 2 DCM data presentation at HFSA meeting next month Quarterly corporate conference call today at 4:30 PM ET ANN ARBOR, Mich., Aug.
View HTML
Toggle Summary Aastrom Announces Adoption of Shareholder Rights Plan
ANN ARBOR, Mich., Aug. 11, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) ("Aastrom" or the "Company"), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that its Board of
View HTML
Toggle Summary Webcast Alert: Aastrom to Host Second Quarter 2011 Investor Call
ANN ARBOR, Mich., Aug. 10, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the following webcast: What: Aastrom Biosciences, Inc.,
View HTML
Toggle Summary Aastrom Announces Agreement From FDA on Special Protocol Assessment for Phase 3 Clinical Trial in No-Option Critical Limb Ischemia Patients
Aastrom Preparing to Begin Phase 3 Clinical Trial in Q4 2011
View HTML
Toggle Summary Journal of Vascular Surgery Publishes Interim Results of RESTORE-CLI Phase 2b Clinical Trial
ANN ARBOR, Mich., June 23, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that data from the Phase 2b RESTORE-CLI clinical
View HTML
Toggle Summary Aastrom Establishes Independent Steering Committee for REVIVE Phase 3 CLI Clinical Program
ANN ARBOR, Mich., June 21, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced the formation of an independent steering committee
View HTML
Toggle Summary Aastrom Files At-the-Market Offering and New Shelf Registration Statement
ANN ARBOR, Mich., June 16, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has filed a prospectus supplement to sell
View HTML
Toggle Summary Aastrom Demonstrates Statistically Significant Improvement in Time to First Occurrence of Treatment Failure at 12 Months in RESTORE-CLI Clinical Trial
RESTORE-CLI Results Meet Primary Safety and Efficacy Endpoints
View HTML
Toggle Summary Webcast Alert: Aastrom to Present Top-Line 12-Month RESTORE-CLI Results
ANN ARBOR, Mich., May 31, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced the following webcast: What:  Aastrom Biosciences,
View HTML
Toggle Summary Aastrom Announces Collaboration With CPC Clinical Research for the Phase 3 REVIVE Study in Critical Limb Ischemia
ANN ARBOR, Mich., May 25, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced a collaborative agreement with CPC Clinical Research
View HTML
Toggle Summary Aastrom to Present Results From Two Studies of Autologous Bone Marrow-Derived ixmyelocel-T at the International Society for Cellular Therapy Meeting
ANN ARBOR, Mich., May 17, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific, expanded multi-cellular therapies for the treatment of severe, chronic cardiovascular diseases, will present results from two studies of the company's bone
View HTML
Toggle Summary Aastrom Biosciences Reports First Quarter 2011 Financial Results and Corporate Developments
Conference Call Today at 4:30 PM ET
View HTML
Toggle Summary Webcast Alert: Aastrom to Host First Quarter 2011 Investor Call
ANN ARBOR, Mich., May 11, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded, patient-specific cellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the following webcast: What: Aastrom Biosciences, Inc., First
View HTML
Toggle Summary Aastrom CEO Tim Mayleben to Present at the World Stem Cells and Regenerative Medicine Congress 2011 in London
ANN ARBOR, Mich., May 6, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded patient-specific cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will present at
View HTML
Toggle Summary Aastrom Announces Key Manufacturing Milestone and New Generic Name for Its Cell Therapy Product
Essential Manufacturing Steps Completed in Preparation for Phase 3 CLI Program
View HTML
Toggle Summary Aastrom to Present at the 10th Annual Needham & Company Healthcare Conference
ANN ARBOR, Mich., April 1, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded patient-specific cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will speak at
View HTML
Toggle Summary Aastrom Announces Date of 2011 Annual Meeting of Shareholders
ANN ARBOR, Mich., March 25, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded, patient specific cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that the company will hold its 2011 Annual Meeting of
View HTML
Toggle Summary Aastrom Announces Outcome of Special Meeting of Shareholders
ANN ARBOR, Mich., March 21, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company shareholders approved amendments to the company's
View HTML
Toggle Summary Aastrom to Present at ROTH Capital Growth Stock Conference
ANN ARBOR, Mich., March 10, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will speak at the
View HTML
Toggle Summary Aastrom to Present at the Cowen 31st Annual Healthcare Conference
ANN ARBOR, Mich., March 4, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will speak at the
View HTML
Toggle Summary Aastrom Biosciences Reports Operating Results for the Quarter and Six Months Ended December 31, 2010
Conference Call Scheduled Today at 4:30 PM EST
View HTML
Toggle Summary Webcast Alert: Aastrom to Report Fourth Quarter and Year-End 2010 Operating Results on February 28, 2011
Special Meeting of Shareholders Scheduled for March 21 to Consider Share Authorizations
View HTML
Toggle Summary Aastrom Announces Restatement of Historical Financial Results to Reflect Reclassification of Warrants
ANN ARBOR, Mich., Feb. 14, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announced today that the company will be restating its financial statements for all periods included in an amended annual report on Form 10-K/A for the fiscal period ended June 30, 2010, as well as amended
View HTML
Toggle Summary Aastrom to Present at 2011 BIO CEO & Investor Conference
ANN ARBOR, Mich., Feb. 11, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will speak at the 13th
View HTML
Toggle Summary Overview of Aastrom RESTORE-CLI and IMPACT-DCM Clinical Results Presented Today at the Conference on Cell Therapy for Cardiovascular Disease
ANN ARBOR, Mich., Jan. 20, 2011 (GLOBE NEWSWIRE) -- Amit N. Patel, MD, MS, associate professor of surgery at the University of Utah School of Medicine and national principal investigator in Aastrom's U.S. Phase 2 IMPACT-DCM clinical trial, and Sharon Watling, Pharm.D., Aastrom's vice president of
View HTML
Toggle Summary Aastrom Receives Key U.S. Composition of Matter Patent for Autologous Cell Therapy
ANN ARBOR, Mich., Jan. 18, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for severe, chronic cardiovascular diseases, today announced that it has been granted a U.S. patent which provides composition of matter
View HTML
Toggle Summary Aastrom Biosciences, Inc. Closes $22.5 Million Public Offering
ANN ARBOR, Mich., Dec. 15, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has completed a public offering of 10,000,000 units at a
View HTML
Toggle Summary Aastrom Biosciences, Inc. Prices $22.5 Million Public Offering
ANN ARBOR, Mich., Dec. 10, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has priced a public offering of 10,000,000 units, with
View HTML
Toggle Summary Aastrom Biosciences, Inc. Announces Proposed Public Offering
ANN ARBOR, Mich., Dec. 9, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it is commencing a public offering of its common stock and
View HTML
Toggle Summary Aastrom Presents Positive Second Interim Analysis of Phase 2b RESTORE-CLI Clinical Trial
Company Continues Its Plans to Rapidly Move Into a Phase 3 Program in 2011
View HTML
Toggle Summary Webcast Alert: Aastrom to Host VEITHsymposium(TM) Satellite Event
ANN ARBOR, Mich., Nov. 11, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following webcast: What: Aastrom will present data from an interim analysis of its Phase 2b RESTORE-CLI clinical trial at a   VEITHsymposium™ non-CME satellite session. This event will include
View HTML
Toggle Summary Aastrom Biosciences Reports Quarterly Operating Results
Preparing for Phase 3 Critical Limb Ischemia Clinical Program Company to Present Phase 2b CLI Interim Data at a VEITHsymposium™ Satellite Session on November 18 at 1:00 p.m. (ET) ANN ARBOR, Mich., Nov. 8, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc.
View HTML
Toggle Summary Webcast Alert: Aastrom to Host First Quarter Investor Conference Call
ANN ARBOR, Mich., Nov. 1, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following webcast: What: Aastrom Biosciences, Inc., First Quarter Fiscal Year 2011 Investor Conference Call                     When: Monday, November 8, 2010 @ 9:30 am (ET)                    
View HTML
Toggle Summary Aastrom to Present at 21st Annual Oppenheimer Healthcare Conference
ANN ARBOR, Mich., Oct. 27, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that Tim Mayleben, president and CEO, will present on behalf of the company
View HTML
Toggle Summary Aastrom and ATEK Medical Form Strategic Manufacturing and Development Partnership
Collaboration Expected to Generate High-Paying Jobs in Michigan
View HTML
Toggle Summary Former Chief Scientific Officer of Warner-Lambert and President of Parke-Davis Pharmaceutical Research Joins Aastrom Board of Directors
ANN ARBOR, Mich., Oct. 25, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that Ronald Cresswell, Ph.D., Hon.
View HTML
Toggle Summary Aastrom Submits Special Protocol Assessment to FDA for Its Phase 3 CLI Program
ANN ARBOR, Mich., Oct. 20, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that it has submitted to the U.S.
View HTML
Toggle Summary Aastrom Receives FDA Fast Track Designation for Phase 3 CLI Program
ANN ARBOR, Mich., Oct. 18, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted fast track
View HTML
Toggle Summary Aastrom to Present at 12th Annual Rodman & Renshaw Global Investment Conference
ANN ARBOR, Mich., Sept. 8, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that Tim Mayleben, president and CEO, will present at the 12th Annual
View HTML
Toggle Summary Aastrom Biosciences Reports Fourth Quarter and Fiscal Year 2010 Operating Results
Company Preparing for Phase 3 Critical Limb Ischemia Clinical Program, Announcement of Final Phase 2 CLI 6-Month Results and Final IMPACT-DCM 6-Month Results
View HTML
Toggle Summary Webcast Alert: Aastrom to Host Fourth Quarter Investor Conference Call
ANN ARBOR, Mich., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following webcast: What: Aastrom Biosciences, Inc. Fourth Quarter Fiscal Year 2010 Investor Conference Call When: Tuesday, August 17, 2010 @ 4:00 pm (ET) Where:
View HTML
Toggle Summary Aastrom Biosciences, Inc. Announces Date of 2010 Annual Meeting of Shareholders
ANN ARBOR, Mich., Aug. 2, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) today announced that it currently plans to hold its 2010 Annual Meeting of Shareholders on October 21, 2010. Shareholders of record as of August 26, 2010 are entitled to notice of and to vote at the 2010
View HTML
Toggle Summary Aastrom Initiates IMPACT-DCM Extension Study for Control Patients
Independent Data Safety Monitoring Board Approves Protocol Amendment for Initiation of Extension Study Involving Control Patients and Encourages Company to Begin Patient Enrollment
View HTML
Toggle Summary Aastrom to Pursue Phase 3 Clinical Program in CLI
ANN ARBOR, Mich., July 6, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the company will pursue a Phase 3 clinical program for its autologous cell
View HTML
Toggle Summary Interim Results From Aastrom Critical Limb Ischemia Study Presented Today at Society for Vascular Surgery Annual Meeting
Additional Results Showing Statistically Significant Improvement in Amputation-Free Survival to be Presented by Principal Investigator Richard Powell, M.D.; Webcast and Conference Call Scheduled for 3:30pm EDT
View HTML
Toggle Summary Scott C. Durbin Joins Aastrom as Chief Financial Officer
ANN ARBOR, Mich., June 8, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that Scott C. Durbin has joined the company as chief financial officer. Mr.
View HTML
Toggle Summary Webcast Alert: Aastrom to Host Investor Conference Call and Webcast on June 11, 2010 Following Presentation at Society for Vascular Surgery Meeting
ANN ARBOR, Mich., June 4, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following webcast: What:  Conference call and webcast of the presentation of interim results from Aastrom's U.S. Phase 2b RESTORE-CLI clinical trial which will be presented at the Vascular
View HTML
Toggle Summary Aastrom to Participate in First Annual Stem Cell Investor & Executive Networking Conference Event
ANN ARBOR, Mich., May 27, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that Ronnda Bartel, Ph.D., chief scientific officer, will participate in a plenary
View HTML
Toggle Summary Aastrom Announces Senior Management Appointments
Ronnda L. Bartel, Ph.D., Named Chief Scientific Officer; Sharon Watling, Pharm.D., Appointed Vice President of Clinical and Regulatory Affairs
View HTML
Toggle Summary First Patient Treated in Aastrom's U.S. Phase 2 Catheter Clinical Trial in Dilated Cardiomyopathy
ANN ARBOR, Mich., May 17, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the first patient has been treated in the company's U.S.
View HTML
Toggle Summary Aastrom Reports Third Quarter Fiscal Year 2010 Financial Results
ANN ARBOR, Mich., May 10, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported financial results for its third fiscal quarter ended March 31, 2010, and also
View HTML
Toggle Summary Webcast Alert: Aastrom to Host Investor Conference Call on Critical Limb Ischemia and Related Clinical Development Progress
Webcast Alert: Aastrom to Host Investor Conference Call on Critical Limb Ischemia and Related Clinical Development Progress Ann Arbor, Michigan, May 3, 2010 (3:20 pm ET) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following webcast: What: Investor conference call to present an update
View HTML
Toggle Summary Interim Results From Aastrom's Vascular Trial to be Presented at Society for Vascular Surgery Annual Meeting
Principal Investigator Dr. Richard Powell to Present Interim Results From U.S. Phase 2b RESTORE-CLI Trial at the 2010 Vascular Annual Meeting(R) on June 11 in Boston, MA
View HTML
Toggle Summary Aastrom Announces Formation of Scientific Advisory Board
Top Cell Biologists and Cardiovascular Disease Experts to Provide Scientific and Clinical Development Counsel
View HTML
Toggle Summary Aastrom Announces Treatment of Final Patient in RESTORE-CLI Clinical Trial
Company Plans to Initiate Phase 3 Planning Discussions With the FDA and Report Six-Month Interim Results for all Enrolled Patients Later This Year
View HTML
Toggle Summary Aastrom Ticker Symbol Reverts to ASTM
ANN ARBOR, Mich., March 18, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) today reported that its ticker symbol will revert back to ASTM as of March 18, 2010. As a result of the company's reverse stock split which became effective as of February 18, 2010, the company's common
View HTML
Toggle Summary Aastrom Announces Treatment of Final Patient in IMPACT-DCM Surgical Clinical Trial
Six-Month Interim Results in Study of Patients With Severe Cardiovascular Disease to be Presented Later This Year
View HTML
Toggle Summary Aastrom Regains Compliance With NASDAQ Minimum Bid Requirement
ANN ARBOR, Mich., March 4, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTMD), a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported that the company has regained compliance with the $1.00 minimum bid price
View HTML
Toggle Summary Aastrom Reports Interim Results From Critical Limb Ischemia Trial
Study meets composite endpoint of reduction in time to treatment failure with statistical significance Company concludes patient enrollment early to accelerate study completion and Phase 3 planning Aastrom to hold investor conference call at 9 a.m. ET to discuss results ANN ARBOR, Mich., Feb.
View HTML
Toggle Summary Aastrom One-for-Eight Reverse Stock Split Now Effective
ANN ARBOR, Mich., Feb. 18, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) today reported that its previously announced one-for-eight reverse stock split of the company's issued and outstanding common shares is now effective. This reverse split is intended to increase the per share
View HTML
Toggle Summary Aastrom Reports Second Quarter Fiscal Year 2010 Financial Results
Company Advances Clinical Development Programs for Investigational Therapies to Treat Severe Cardiovascular Diseases
View HTML
Toggle Summary Aastrom Announces One-for-Eight Reverse Stock Split
ANN ARBOR, Mich., Feb. 9, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences (Nasdaq:ASTM) announced today that its board of directors has approved a one-for-eight reverse stock split of the company's common stock effective on February 18, 2010. The company has filed an amendment to its articles of
View HTML
Toggle Summary Aastrom Biosciences Announces Closing of Unit Offering
ANN ARBOR, Mich., Jan. 21, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced the closing of its previously announced underwritten public offering from which the
View HTML
Toggle Summary Aastrom Biosciences Announces Pricing of Unit Offering
ANN ARBOR, Mich., Jan. 15, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced the pricing of its previously announced underwritten public offering of 46,154,000 units
View HTML
Toggle Summary Aastrom Biosciences Announces Proposed Public Offering of Units
ANN ARBOR, Mich., Jan. 14, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced that it intends to offer to sell, subject to market and other conditions, units
View HTML
Toggle Summary Aastrom Biosciences Shareholders Approve All 2009 Proxy Proposals
ANN ARBOR, Mich., Dec. 21, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of severe, chronic cardiovascular diseases, announced today that shareholders of the Company approved all five proxy proposals at the Annual
View HTML
Toggle Summary NASDAQ Hearings Panel Grants Exception Period to Aastrom Based on Request to Remain Listed on the NASDAQ Stock Market
ANN ARBOR, Mich., Dec. 9, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of severe, chronic cardiovascular diseases, announced today that the NASDAQ Hearings Panel (Panel) has granted the Company's request to
View HTML
Toggle Summary Webcast Alert: Aastrom Biosciences Announces Webcast for Annual Meeting of Shareholders
Webcast Alert: Aastrom Biosciences Announces Webcast for Annual Meeting of Shareholders Ann Arbor, MI, December 9, 2009 -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences Fiscal Year 2009 Annual Meeting of Shareholders When: Monday, December 14, 2009 @
View HTML
Toggle Summary Updates and Results From Aastrom's Vascular Program Presented at an American Heart Association Satellite Symposium
Physicians Present Continued Progress in Company's Vascular Clinical Program
View HTML
Toggle Summary Interim Results From Aastrom's IMPACT-DCM Cardiac Trial Presented at The American Heart Association Meeting
National PI Presents Encouraging Progress in U.S. Cardiac Clinical Trial
View HTML
Toggle Summary Aastrom to Initiate Second Phase II Clinical Trial for Treatment of Severe Chronic Heart Failure
Catheter-Based Delivery of CRCs by Cardiologists to Expand Company's Ongoing Cardiovascular Program
View HTML
Toggle Summary Aastrom Biosciences Reports First Quarter Fiscal Year 2010 Financial Results
Focus on Cardiovascular Regeneration Sets Foundation for Continued Clinical Progress
View HTML
Toggle Summary Harold C. Urschel, Jr., M.D. Joins Aastrom Biosciences' Board of Directors
Distinguished Cardiovascular and Thoracic Surgeon and Chair of Cardiovascular & Thoracic Surgical Research, Education & Clinical Excellence at Baylor University Medical Center to Strengthen Company's Board
View HTML
Toggle Summary Aastrom Receives Letter From NASDAQ Regarding Continued Non-Compliance With Minimum Bid Price Rule
Company Meets All Other NASDAQ Capital Market Initial Listing Requirements Other Than the $1.00 Minimum Bid Price Rule; Company Will Request Hearing to Present Plans for Regaining Compliance; Company to Remain Listed On NASDAQ Capital Market During Hearing Process
View HTML
Toggle Summary Aastrom Biosciences to Present At Maxim Group Growth Conference
ANN ARBOR, Mich., Sept. 24, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today announced that George Dunbar, President and Chief Executive Officer, will present at the Maxim
View HTML
Toggle Summary Update On Aastrom's Cardiovascular Programs to be Presented At Transcatheter Cardiovascular Therapeutics Annual Meeting by Amit N. Patel, M.D.
Momentum of Current Clinical Trial Recruitment Continues; Clinical Trial Pipeline for Severe Heart Failure Patients Expanding
View HTML
Toggle Summary Aastrom Biosciences Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Adult Stem Cell Patient Treatments Progress in U.S. Phase II Cardiac and Vascular Regeneration Clinical Trials; Patient Enrollment On Track With Guidance
View HTML
Toggle Summary Aastrom Announces Transitions in Senior Management
Industry Veteran and Aastrom Board Member, Tim Mayleben, to Become New CEO in December 2009; Expected That George Dunbar, Current CEO, Will Become Chairman of the Board; Transitions to Strengthen and Expand Senior Management Team to Become Effective Immediately After Company's Annual Meeting Currently Set for December 14, 2009
View HTML
Toggle Summary Compassionate Use Patients in Spain Treated With Adult Stem Cell Therapy Demonstrate Jaw Bone Regeneration Enabling Dental Implants
Results From Three Patient Treatments Involving Investigational Stem Cell Therapy Developed by Aastrom Biosciences Presented During the 2nd Annual Congress of Regenerative Medicine & Stem Cell in Dalian, China
View HTML
Toggle Summary Aastrom Biosciences to Present At BMO Capital Markets Healthcare Conference
ANN ARBOR, Mich., Aug. 3, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today announced that George Dunbar, President and Chief Executive Officer, and Elmar Burchardt, MD,
View HTML
Toggle Summary Aastrom Biosciences Receives Notification That NASDAQ to Continue Temporary Suspension of Certain Continued Listing Requirements
Aastrom Has Until October 1, 2009 to Regain Compliance
View HTML
Toggle Summary FDA Removes Clinical Hold From Aastrom Phase II IMPACT-DCM Clinical Trial
Patient Death Unrelated to Aastrom's CRCs; Trial to Resume At All Clinical Sites for Patients Suffering From Dilated Cardiomyopathy
View HTML
Toggle Summary Aastrom Proactively Places Phase II IMPACT-DCM Clinical Trial On Hold Following Report of Serious Adverse Event
Treatment Patient Released From Hospital Later Dies; Investigation Underway to Determine Cause of Death
View HTML
Toggle Summary Aastrom Reports Third Quarter Fiscal Year 2009 Financial Results
ANN ARBOR, Mich., May 8, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today reported financial results for the third fiscal quarter ended March 31, 2009.
View HTML
Toggle Summary Initial Data From Aastrom's IMPACT-DCM Trial Presented At International Society for Cellular Therapy Annual Meeting by Amit N. Patel, M.D.
Encouraging Early Data Reported in Severe Heart Failure Patients With Dilated Cardiomyopathy
View HTML
Toggle Summary Aastrom Biosciences Receives Notification That NASDAQ Further Extends Suspension of Certain Continued Listing Requirements
Aastrom Has Until September 18, 2009 to Regain Compliance
View HTML
Toggle Summary Aastrom Commends Expansion of Federal Support for Stem Cell Research
ANN ARBOR, Mich., March 10, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today commended the expansion of federal support designed to advance stem cell research.
View HTML
Toggle Summary FDA Removes Clinical Hold From Aastrom Phase II IMPACT-DCM Clinical Trial
Trial to Resume At Four Clinical Sites for Patients Suffering From Dilated Cardiomyopathy
View HTML
Toggle Summary Aastrom Reports Second Quarter Fiscal Year 2009 Financial Results
Continued Clinical Progress Reported From Cardiovascular Programs
View HTML
Toggle Summary Aastrom Biosciences to Present At the 11th Annual BIO CEO & Investor Conference
ANN ARBOR, Mich., Feb. 4, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that George W. Dunbar, President and Chief Executive Officer, will present at the 11th Annual BIO CEO & Investor Conference.
View HTML
Toggle Summary Aastrom Phase II IMPACT-DCM Clinical Trial Placed On Clinical Hold Pending Review of Isolated Serious Adverse Event Related to Anesthesia Management in One Patient
ANN ARBOR, Mich., Feb. 2, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today reported that one patient enrolled in the Company's U.S. Phase II IMPACT-DCM clinical trial experienced a serious adverse event associated with anesthesia
View HTML
Toggle Summary Aastrom Announces Treatment of First Patient in U.S. Phase II IMPACT-DCM Trial
ANN ARBOR, Mich., Nov. 20, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the first patient has been treated in its randomized, controlled, prospective, open-label IMPACT-DCM clinical trial.
View HTML
Toggle Summary Aastrom Biosciences to Present At Rodman & Renshaw 10th Annual Healthcare Conference
ANN ARBOR, Mich., Nov. 7, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that Martin C. Peters, PhD, Senior Director, Business Strategy & Market Development, will present at the Rodman & Renshaw 10th Annual Healthcare
View HTML
Toggle Summary Aastrom Biosciences Reports First Quarter Fiscal Year 2009 Financial Results
ANN ARBOR, Mich., Nov. 7, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today reported financial results for the first fiscal quarter ended September 30, 2008. The Company also reported several recent clinical and operational
View HTML
Toggle Summary Aastrom Announces Achievement of Milestone in U.S. Phase IIb Critical Limb Ischemia Clinical Trial
ANN ARBOR, Mich., Oct. 30, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the 30th patient has been treated in the Company's U.S. Phase IIb RESTORE-CLI clinical trial. This milestone marks the first step toward interim
View HTML
Toggle Summary Aastrom Biosciences Receives Notification That NASDAQ Issued Temporary Suspension of Certain Continued Listing Requirements
ANN ARBOR, Mich., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, announced that the Company received notification from the Listings Qualifications Department of The Nasdaq Stock Market LLC ("NASDAQ") that, given the current
View HTML
Toggle Summary Aastrom Biosciences, Inc. Proxy Proposals Approved
Aastrom Biosciences, Inc. Proxy Proposals Approved ANN ARBOR, Mich., Oct. 27, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (NasdaqCM: ASTM - News ), a leading regenerative medicine company, today announced that shareholders of the Company approved all fiscal year 2008 proxy proposals at the
View HTML
Toggle Summary Webcast Alert: Aastrom Biosciences Announces Webcast for Annual Meeting of Shareholders
ANN ARBOR, Mich., Oct. 13, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences (Nasdaq:ASTM) announces the following Webcast: What: Aastrom Biosciences Fiscal Year 2008 Annual Meeting of Shareholders When: Friday, October 17, 2008 @ 9:00 am (Eastern) Where:
View HTML
Toggle Summary Institutional Shareholder Services, Inc. Recommends Aastrom Shareholders Vote 'FOR' Fiscal Year 2008 Good Corporate Governance Proxy Proposals
ANN ARBOR, Mich., Sept. 29, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that Institutional Shareholder Services, Inc. (ISS), a wholly-owned subsidiary of RiskMetrics Group, Inc., one of the nation's leading proxy
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports Fourth Quarter and Fiscal Year 2008 Financial Results
ANN ARBOR, Mich., Aug 29, 2008 (GlobeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today reported financial results for the fourth quarter and fiscal year ended June 30, 2008. The Company also reported clinical and operational
View HTML
Toggle Summary Webcast Alert: Aastrom Announces Fourth Quarter Investor Conference Call
ANN ARBOR, Mich., Aug 26, 2008 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ:ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. 4th Quarter Fiscal Year 2008 Investor Conference Call When: Friday, August 29, 2008 @ 11:00 am (EDT) Where:
View HTML
Toggle Summary Aastrom Biosciences to Present At BMO Capital Markets Healthcare Conference
ANN ARBOR, Mich., Jul 31, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) ), a leading regenerative medicine company, today announced that George Dunbar, President and Chief Executive Officer, will present at the 2008 BMO Capital Markets Focus on Healthcare
View HTML
Toggle Summary Aastrom Biosciences Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
ANN ARBOR, Mich., Jun 18, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that on June 18, 2008 the Company received a notice from The Nasdaq Stock Market (Nasdaq) informing the Company, that pursuant
View HTML
Toggle Summary Aastrom to Initiate Phase II Clinical Trial Using Cardiac Repair Cells Derived From Patient's Own Bone Marrow for Treatment of Severe Chronic Heart Failure
FDA Authorizes IND Application for Aastrom's First Cardiac Regeneration Clinical Trial
View HTML
Toggle Summary Aastrom Reports Third Quarter Fiscal Year 2008 Financial Results
ANN ARBOR, Mich., May 12, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today reported financial results for the third fiscal quarter ended March 31, 2008. Since the beginning of the third fiscal quarter, the
View HTML
Toggle Summary Webcast Alert: Aastrom Announces Third Quarter Investor Conference Call
ANN ARBOR, Mich., May 08, 2008 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. Third Quarter Fiscal Year 2008 Investor Conference Call When: Monday, May 12, 2008 @ 4:15 pm (Eastern) Where:
View HTML
Toggle Summary Aastrom Biosciences Board of Directors Withdraws Reverse Stock Split Proposal
ANN ARBOR, Mich., May 5, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that its Board of Directors will withdraw its proposal to shareholders for approval of the grant of discretionary authority to
View HTML
Toggle Summary Aastrom Event Reminder: Q&A Sessions Regarding Shareholder Proposal
ANN ARBOR, Mich., Apr 23, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) will host two one-hour telephone Question & Answer sessions to provide further clarity on the proposal to amend the Company's Restated Articles of Incorporation to position the
View HTML
Toggle Summary Encouraging Clinical Data Reported From Aastrom's First EU Compassionate Use Cardiac Patients
Company Lays Foundation for U.S. Cardiac Clinical Program
View HTML
Toggle Summary Aastrom Biosciences Adjourns Special Meeting Until May 6, 2008; Board Urges Shareholders to Vote for the Proposal Considered Critical to the Future of the Company
Additional Time Provided for Greater Shareholder Turnout to Support Reverse Split Authorization Proposal
View HTML
Toggle Summary Aastrom Biosciences Intends to Seek Shareholder Approval to Grant Board Authority to Amend Restated Articles of Incorporation
ANN ARBOR, Mich., Feb 22, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the Company intends to seek shareholder approval to authorize the Board of Directors to amend Aastrom's Restated Articles
View HTML
Toggle Summary Aastrom Biosciences Announces Transition of Duties
ANN ARBOR, Mich., Feb 15, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that Gerald D. Brennan, Jr., Vice President, Administrative & Financial Operations and Chief Financial Officer, has announced
View HTML
Toggle Summary Aastrom Reports Second Quarter Fiscal Year 2008 Financial Results
Continued Clinical Progress Reported From Tissue Regeneration Programs
View HTML
Toggle Summary Webcast Alert: Aastrom Announces Second Quarter Investor Conference Call
ANN ARBOR, Mich., Jan 31, 2008 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. Second Quarter Fiscal Year 2008 Investor Conference Call When: Friday, February 8, 2008 @ 9:00 am (Eastern) Where:
View HTML
Toggle Summary Aastrom Biosciences to Present At Leerink Swann Novel Biologics Therapeutics Roundtable Conference
ANN ARBOR, Mich., Jan 17, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) ), a leading regenerative medicine company, today announced that George Dunbar, President and Chief Executive Officer, will participate in the Leerink Swann Novel Biologics Therapeutics
View HTML
Toggle Summary Aastrom Announces First Patient Treatment With Autologous Stem Cell Therapy for Heart Failure
Company Milestone Achieved by Initiating Treatments in Heart Failure Patients With Dilated Cardiomyopathy -- a Severe Chronic Disease of the Heart
View HTML
Toggle Summary Aastrom Biosciences Receives Notice Related to NASDAQ Minimum Closing Bid Price Rule
ANN ARBOR, Mich., Dec 21, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that on December 20, 2007, the Company received a deficiency letter from The Nasdaq Stock Market indicating that the minimum
View HTML
Toggle Summary Aastrom Biosciences to Present At RBC Capital Markets Healthcare Conference
ANN ARBOR, Mich., Dec 7, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that George Dunbar, President and Chief Executive Officer, will participate in the Biomaterials: Helping The Body Regenerate
View HTML
Toggle Summary Aastrom Biosciences to Present At BMO Capital Markets Healthcare Conference
ANN ARBOR, Mich., Nov 29, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that George Dunbar, President and Chief Executive Officer, will present at the 2007 BMO Capital Markets Focus on Healthcare
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports First Quarter Fiscal Year 2008 Financial Results
Clinical Progress Reported From Tissue Regeneration Programs
View HTML
Toggle Summary Webcast Alert: Aastrom Announces First Quarter Investor Conference Call
ANN ARBOR, Mich., Nov 05, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. First Quarter Fiscal Year 2008 Investor Conference Call When: Friday, November 9, 2007 @ 9:00 am (Eastern) Where:
View HTML
Toggle Summary Webcast Alert: Aastrom Biosciences Announces Webcast for Annual Meeting of Shareholders
ANN ARBOR, Mich., Oct 31, 2007 (BUSINESS WIRE) -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences Fiscal Year 2007 Annual Meeting of Shareholders When: Wednesday, November 7, 2007 @ 9:00 am (Eastern) Where: http://www.vcall.com/IC/CEPage.asp?ID=122044
View HTML
Toggle Summary Aastrom Biosciences to Present At Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference
ANN ARBOR, Mich., Oct 30, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that Gerald D. Brennan, Vice President, Administrative and Financial Operations and Chief Financial Officer and Elmar R.
View HTML
Toggle Summary Aastrom Stem Cell Therapy Demonstrates Positive Results in Severe Long Bone Non-Union Fracture Trial
Phase I/II Study Results Presented Today at the Orthopaedic Trauma Association Annual Meeting Show a Healing Rate of 91 Percent in Patients With Non-Union Tibia, Humerus or Femur Fractures Who Failed to Heal After One or More Medical Procedures
View HTML
Toggle Summary Aastrom Biosciences to Raise $13.5 Million in Registered Direct Offering
ANN ARBOR, Mich., Oct 16, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, announced today that it has executed definitive Purchase Agreements for the sale of approximately 11.8 million Units in a registered direct
View HTML
Toggle Summary Webcast Alert: Aastrom Announces Conference Call to Discuss the Results from the U.S. Phase I/II Severe Fracture Trial
ANN ARBOR, Mich., Oct 16, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. Conference Call to Discuss the Results from the U.S. Phase I/II Severe Fracture Trial When: Monday, October 22, 2007 at 9:00 am (EDT) Where:
View HTML
Toggle Summary Aastrom Announces Positive Interim Results From Phase I/II Study Involving Use of Vascular Repair Cells in Patients With Critical Limb Ischemia
Oct 4, 2007 (PrimeNewswire via COMTEX News Network) -- Results Presented Today At the Congress of the German Society for Stem Cell Research in Wurzburg, Germany Early Clinical Data Supporting Use of Aastrom Bone Repair Cells (Brcs) in Treatment of Osteonecrosis of the Femoral Head Also Presented
View HTML
Toggle Summary Aastrom Biosciences to Present at UBS Global Life Sciences Conference
ANN ARBOR, Mich., Sep 19, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) today announced that Gerald D. Brennan, Jr., Vice President, Administrative & Financial Operations and Chief Financial Officer, will present at the UBS Global Life Sciences Conference.
View HTML
Toggle Summary Aastrom Biosciences to Present At Merriman Curhan Ford & Co. 4th Annual Investor Summit
ANN ARBOR, Mich., Sep 13, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) today announced that Sheldon A. Schaffer, Ph.D., Vice President, Corporate Development & Intellectual Property, will present at the Merriman Curhan Ford & Co.
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results
ANN ARBOR, Mich., Sep 10, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a regenerative medicine company, today reported financial results for the fourth quarter and fiscal year ended June 30, 2007. The Company also reported clinical and operational
View HTML
Toggle Summary Webcast Alert: Aastrom Announces Fourth Quarter Investor Conference Call
ANN ARBOR, Mich., Sep 04, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. 4th Quarter Fiscal Year 2007 Investor Conference Call When: Monday, September 10, 2007 @ 4:30 pm (EDT) Where:
View HTML
Toggle Summary Aastrom Granted Tax Savings to Encourage Local Business Development
Adult Stem Cell Company Slated for Growth in Ann Arbor Township
View HTML
Toggle Summary First Patient Treated in Aastrom Adult Stem Cell Trial for Critical Limb Ischemia
Five Sites Initiated for Phase IIb Trial in U.S.
View HTML
Toggle Summary Aastrom Reports Third Quarter Fiscal Year 2007 Financial Results
Company Achieves Multiple Clinical Milestones; Initiates Several Clinical Trials
View HTML
Toggle Summary FDA Approves Aastrom Phase III IND for Treatment of Osteonecrosis of the Femoral Head
Patient-Specific Stem Cell Trial to Address Unmet Medical Need
View HTML
Toggle Summary Webcast Alert: Aastrom Announces Its Third Quarter Investor Conference Call
ANN ARBOR, Mich., May 03, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. 3rd Quarter Fiscal Year 2007 Investor Conference Call When: Tuesday, May 8, 2007 @ 9:00 am (EDT) Where:
View HTML
Toggle Summary Aastrom Initiates Adult Stem Cell Clinical Trial for Peripheral Arterial Disease
FDA-Approved Phase IIb Trial Underway in U.S. to Treat Critical Limb Ischemia
View HTML
Toggle Summary Aastrom to Present at Cowen & Company 27th Annual Health Care Conference
ANN ARBOR, Mich., March 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), a company developing cell-based therapeutics for regenerative medicine, today announced that Gerald D. Brennan, Jr., Vice President, Administrative & Financial Operations and
View HTML
Toggle Summary Aastrom's U.S. Clinical Investigator to Report Interim Data on Long Bone Fracture Repair Trial
-- Additional Positive Patient Treatment Results Presented at the American Academy of Orthopaedic Surgeons Meeting --
View HTML
Toggle Summary Aastrom Reports Second Quarter Fiscal Year 2007 Financial Results
ANN ARBOR, Mich., Feb 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), a company developing cell-based therapeutics for regenerative medicine, today reported financial results for the second fiscal quarter ended December 31, 2006.
View HTML
Toggle Summary Webcast Alert: Aastrom Biosciences Announces Its Second Quarter Investor Conference Call
ANN ARBOR, Mich., Feb 02, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. 2nd Quarter Fiscal Year 2007 Investor Conference Call When: Wednesday, February 7, 2007 @ 9:00 am (EST) Where:
View HTML
Toggle Summary Aastrom Receives Orphan Drug Designation from FDA for Dilated Cardiomyopathy
- Up to 150,000 People in U.S. Currently Suffer from this Severe Chronic Heart Disease
View HTML
Toggle Summary Aastrom Treats Patients in Adult Stem Cell Clinical Trial for Osteonecrosis
- Pivotal Bone Regeneration Trial Underway in Spain -
View HTML
Toggle Summary Sheldon A. Schaffer, Ph.D. Joins Aastrom As Vice President, Corporate Development & Intellectual Property
-- Appointment Supports New Initiatives --
View HTML
Toggle Summary Aastrom Biosciences to Present at RBC Capital Markets Healthcare Conference
Aastrom Biosciences to Present at RBC Capital Markets Healthcare Conference Ann Arbor, Michigan, December 7, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), a clinical development stage company focused on the use of autologous cells for regenerative medicine, today announced that George W.
View HTML
Toggle Summary Aastrom Biosciences to Present at BMO Capital Markets Healthcare Conference
Aastrom Biosciences to Present at BMO Capital Markets Healthcare Conference Ann Arbor, Michigan, November 30, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) ), a clinical development stage company focused on the use of autologous cells for regenerative medicine, today announced that George W.
View HTML
Toggle Summary Stephen G. Sudovar Elected Chairman of Aastrom Biosciences' Board of Directors
Stephen G. Sudovar Elected Chairman of Aastrom Biosciences' Board of Directors Ann Arbor, Michigan, November 16, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), a clinical development stage company focused on the use of autologous cells for regenerative medicine, announced today that Stephen G.
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports First Quarter Fiscal Year 2007 Financial Results
Company Reports Clinical Progress and Strengthened Management Team
View HTML
Toggle Summary Webcast Alert: Aastrom Biosciences Announces Its First Quarter Investor Conference Call
Webcast Alert: Aastrom Biosciences Announces Its First Quarter Investor Conference Call Ann Arbor, MI, November 3, 2006 -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. First Quarter Fiscal Year 2007 Investor Conference Call When:
View HTML
Toggle Summary Aastrom Biosciences to Present at Rodman & Renshaw
Aastrom Biosciences to Present at Rodman & Renshaw Ann Arbor, Michigan, November 2, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that George W. Dunbar, President and Chief Executive Officer, and Elmar R. Burchardt, MD, PhD, Vice President, Medical Affairs, will present at the
View HTML
Toggle Summary Webcast Alert: Aastrom Biosciences Announces Webcast of Its Annual Meeting of Shareholders
Webcast Alert: Aastrom Biosciences Announces Webcast of Its Annual Meeting of Shareholders Ann Arbor, MI, October 27, 2006 -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences Fiscal Year 2006 Annual Meeting of Shareholders When: Thursday, November 2,
View HTML
Toggle Summary Ronnda L. Bartel, Ph.D. Joins Aastrom Biosciences As Vice President Research & Development
Ronnda L. Bartel, Ph.D. Joins Aastrom Biosciences As Vice President Research & Development Ann Arbor, Michigan, October 16, 2006 – Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that Ronnda L. Bartel, Ph.D. has joined the Company as Vice President of Research and Development. Dr.
View HTML
Toggle Summary Aastrom Biosciences to Present at BIO Investor Forum
Aastrom Biosciences to Present at BIO Investor Forum Ann Arbor, Michigan, October 12, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that George W. Dunbar, President and Chief Executive Officer, will be presenting at the 2006 BIO Investor Forum.
View HTML
Toggle Summary Aastrom Biosciences' CFO to Present at Noble Financial Group Small Cap Conference
Aastrom Biosciences' CFO to Present at Noble Financial Group Small Cap Conference Ann Arbor, Michigan, September 21, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that Gerald D. Brennan, Jr., Vice President Administrative & Financial Operations and Chief Financial Officer, will
View HTML
Toggle Summary Aastrom Biosciences Reports Interim Data From Long Bone Non-Union Fracture Clinical Trial
Promising Results Demonstrated in Patients
View HTML
Toggle Summary Aastrom Biosciences to Present at Merriman Curhan Ford & Co. 3rd Annual Investor Summit
Aastrom Biosciences to Present at Merriman Curhan Ford & Co. 3rd Annual Investor Summit Ann Arbor, Michigan, September 14, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that George W. Dunbar, President and Chief Executive Officer, Gerald D.
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports Fourth Quarter and Fiscal Year 2006 Financial Results
Ann Arbor, Michigan, September 13, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today reported financial results for the fourth quarter and fiscal year ended June 30, 2006. The Company also reported several clinical and operational achievements during the quarter, including: Completion of the
View HTML
Toggle Summary Webcast Alert: Aastrom Biosciences Announces Its Fourth Quarter Investor Conference Call
Webcast Alert: Aastrom Biosciences Announces Its Fourth Quarter Investor Conference Call Ann Arbor, MI, September 6, 2006 -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. Fourth Quarter Fiscal Year End 2006 Investor Conference Call When:
View HTML
Toggle Summary Aastrom Biosciences Appoints Senior Director Medical Affairs
AASTROM BIOSCIENCES APPOINTS SENIOR DIRECTORMEDICAL AFFAIRS
View HTML
Toggle Summary George W. Dunbar Joins Aastrom Biosciences as Chief Executive Officer
GEORGE W. DUNBAR JOINS AASTROM BIOSCIENCESAS CHIEF EXECUTIVE OFFICER
View HTML
Toggle Summary Aastrom Biosciences Achieves U.S. Bone Fracture Clinical Milestone
AASTROM BIOSCIENCES ACHIEVES U.S. BONE FRACTURECLINICAL MILESTONE
View HTML
Toggle Summary Aastrom Biosciences' CEO to Present at Rodman & Renshaw 3rd Annual Global Healthcare Conference
AASTROM BIOSCIENCES' CEO TO PRESENT AT RODMAN & RENSHAW 3rd ANNUAL GLOBAL HEALTHCARE CONFERENCE
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports Third Quarter Fiscal Year 2006 Financial Results
AASTROM BIOSCIENCES, INC. REPORTS THIRD QUARTERFISCAL YEAR 2006 FINANCIAL RESULTS
View HTML
Toggle Summary Aastrom Biosciences Receives Manufacturing License at European Pilot Facility for...
AASTROM BIOSCIENCES' RECEIVES MANUFACTURING LICENSEAT EUROPEAN PILOT FACILITY FOR PRODUCTION OFPROPRIETARY BONE MARROW STEM CELL PRODUCTS
View HTML
Toggle Summary Webcast Alert: Aastrom Biosciences Announces Its Third Quarter Investor Conference Call
Webcast Alert: Aastrom Biosciences Announces ItsThird Quarter Investor Conference Call
View HTML
Toggle Summary Aastrom Biosciences to Raise $25.5 Million in Equity Financing
Aastrom Biosciences to Raise $25.5 Million in Equity Financing Ann Arbor, Michigan, April 6, 2006 – Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that it has executed definitive Purchase Agreements for the sale of approximately 15.9 million shares of the Company's common stock in a
View HTML
Toggle Summary Aastrom Biosciences Receives Orphan Drug Designation from the FDA for Proprietary Bone Marrow Cells
Aastrom Biosciences Receives Orphan Drug Designation from the FDA for Proprietary Bone Marrow Cells Ann Arbor, Michigan, March 23, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), announced today that the Company's proprietary Tissue Repair Cells (TRCs) received an Orphan Drug Designation from the
View HTML
Toggle Summary Aastrom Biosciences' U.S. Clinical Investigator to Report on Long Bone Fracture Repair Trial
Aastrom Biosciences' U.S. Clinical Investigator to Report on Long Bone Fracture Repair Trial Ann Arbor, Michigan, March 22, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that Matthew L. Jimenez, M.D. will present results from his early clinical experience with the first seven
View HTML
Toggle Summary Orthovita and Aastrom Biosciences Announce Collaboration Agreement for Orthopedic Products
Orthovita and Aastrom Biosciences Announce Collaboration Agreement for Orthopedic Products Ann Arbor, MI and Malvern, PA, March 20, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) and Orthovita, Inc. (Nasdaq: VITA) jointly announced today they have signed an agreement to develop products for the
View HTML
Toggle Summary Aastrom Biosciences' Delegates to Present at Two Orthopaedic Meetings
Aastrom Biosciences' Delegates to Present at Two Orthopaedic Meetings Ann Arbor, Michigan, March 16, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that Company representatives are scheduled to speak at the Stem Cell Summit, and at a symposia at the combined meetings of the
View HTML
Toggle Summary Aastrom Biosciences CEO to Present at Cowen & Co. 26th Annual Health Care Conference
Aastrom Biosciences CEO to Present at Cowen & Co. 26th Annual Health Care Conference Ann Arbor, Michigan, March 2, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today R. Douglas Armstrong, Ph.D., Chairman and Chief Executive Officer, will present at the Cowen & Co.
View HTML
Toggle Summary Nelson M. Sims Joins Aastrom Biosciences' Board of Directors
Nelson M. Sims Joins Aastrom Biosciences' Board of Directors Ann Arbor, Michigan, February 13, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that Nelson M. Sims has been elected to the Company's Board of Directors.  He will serve as a Class III Director whose initial term expires
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports Second Quarter Fiscal Year 2006 Financial Results
Aastrom Biosciences, Inc. Reports Second Quarter Fiscal Year 2006 Financial Results Ann Arbor, Michigan, February 8 , 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today reported financial results for the second fiscal quarter ended December 31, 2005.
View HTML
Toggle Summary Webcast Alert: Aastrom Biosciences Announces Its Second Quarter Investor Conference Call
Webcast Alert: Aastrom Biosciences Announces Its Second Quarter Investor Conference Call Ann Arbor, MI, February 6, 2006 -- Aastrom Biosciences (NASDAQ: ASTM ) announces the following Webcast:   What:       Aastrom Biosciences Second Quarter Fiscal Year End 2006 Investor Conference Call   When:
View HTML
Toggle Summary Robert L. Zerbe, MD, Joins Aastrom Biosciences' Board of Directors
Robert L. Zerbe, MD, Joins Aastrom Biosciences' Board of Directors ROBERT L. ZERBE, M.D., JOINS AASTROM BIOSCIENCES' BOARD OF DIRECTORS Ann Arbor, Michigan, January 17, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that Robert L. Zerbe, M.D.
View HTML
Toggle Summary Aastrom Biosciences Announces Management Succession Process
-- Long-Term CEO and Chairman to Continue at Board Level --
View HTML
Toggle Summary Aastrom Biosciences Reports Positive Human Jaw Bone Reconstruction Results from Feasibility Clinical Trial
-- Results Indicate Company's Tissue Repair Cell Product Safely Builds New Bone for Dental Implants --
View HTML
Toggle Summary Aastrom Biosciences Announces Second Clinical Trial for Bone Fractures in Spain
-- New Trial Expected to Further Company's Knowledge of Bone Regeneration --
View HTML
Toggle Summary Aastrom Biosciences to Initiate U.S. Clinical Trial for Bone Formation in Spine Under Approved IND From the FDA
-- Spine Fusion Trial at William Beaumont Hospital to Use Aastrom's Adult Stem Cell TRC Product --
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports First Quarter Fiscal Year 2006 Financial Results
Aastrom Biosciences, Inc. Reports First Quarter Fiscal Year 2006 Financial Results Ann Arbor, Michigan, November 9 , 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today reported financial results for the first quarter of fiscal year 2006 ended September 30, 2005.  The Company also reported
View HTML
Toggle Summary Aastrom Biosciences CEO to Present at Noble Financial Group Small Cap Conference
Aastrom Biosciences CEO to Present at Noble Financial Group Small Cap Conference Ann Arbor, Michigan, November 7, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today R. Douglas Armstrong, Ph.D., Chairman and Chief Executive Officer, will present at the Noble Financial Group Small Cap
View HTML
Toggle Summary Webcast Alert: Aastrom Biosciences Announces Its First Quarter Investor Conference Call
Webcast Alert: Aastrom Biosciences Announces Its First Quarter Investor Conference Call Ann Arbor, MI, November 4, 2005 -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences First Quarter Fiscal Year End 2006 Investor Conference Call When: Wednesday,
View HTML
Toggle Summary Aastrom Biosciences CEO to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference
Aastrom Biosciences CEO to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference Ann Arbor, Michigan, November 3, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today R. Douglas Armstrong, Ph.D., Chairman and Chief Executive Officer, will present at the Rodman & Renshaw
View HTML
Toggle Summary Webcast Alert: Aastrom Biosciences Announces Webcast of Its Annual Meeting of Shareholders
Webcast Alert: Aastrom Biosciences Announces Webcast of Its Annual Meeting of Shareholders Ann Arbor, MI, November 1, 2005 -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences Fiscal Year End 2005 Annual Meeting of Shareholders When: Wednesday, November
View HTML
Toggle Summary Aastrom Receives Phase II NIH Grant to Support Further Development of Its Proprietary Stem Cell Manufacturing Systems
Aastrom Receives Phase II NIH Grant to Support Further Development of Its Proprietary Stem Cell Manufacturing Systems Ann Arbor, Michigan, October 18, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that it has received a Small Business Innovation Research Phase II grant from the
View HTML
Toggle Summary Aastrom Biosciences' TRCs Used in New Clinical Trial for Regeneration of Vascular Tissue in Diabetic Patients
-- Novel Treatment Utilizes Company's Adult Bone Marrow Stem Cell Product --
View HTML
Toggle Summary Alan L. Rubino Elected to Aastrom Biosciences' Board of Directors
Alan L. Rubino Elected to Aastrom Biosciences' Board of Directors Ann Arbor, Michigan, September 30, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that Alan L. Rubino, a Principal with Watchung Partners, has been elected to the Company's Board of Directors.
View HTML
Toggle Summary Aastrom Biosciences' CEO to Present at the UBS Global Life Sciences Conference
Aastrom Biosciences' CEO to Present at the UBS Global Life Sciences Conference Ann Arbor, Michigan, September 23, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman, will present at the UBS Global Life Sciences
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports Fourth Quarter 2005 Financial Results
Aastrom Biosciences, Inc. Reports Fourth Quarter 2005 Financial Results Ann Arbor, Michigan, September 8, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today reported financial results for the fourth quarter and fiscal year ended June 30, 2005.  The Company also reported significant clinical and
View HTML
Toggle Summary Aastrom Announces Its Fourth Quarter and Fiscal Year End Investor Conference Call
Aastrom Announces Its Fourth Quarter and Fiscal Year End Investor Conference Call Ann Arbor, MI, September 7 -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences Fourth Quarter and Fiscal Year End FY2005 Investor Conference Call When: Thursday, September
View HTML
Toggle Summary Aastrom Biosciences Receives NIH Grant Extending Proprietary Adult Stem Cell Process to Other Tissues
-- Phase II Grant to Support Bone Formation and Vascularization Capabilities of Company's Tissue Repair Cells --
View HTML
Toggle Summary Stephen G. Sudovar Elected to Aastrom Biosciences' Board of Directors
Stephen G. Sudovar Elected to Aastrom Biosciences' Board of Directors Ann Arbor, Michigan, August 2, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that Stephen G. Sudovar, former President and CEO of EluSys Therapeutics, Inc. and former President of Roche Laboratories, Inc., has
View HTML
Toggle Summary Aastrom Biosciences Expands U.S. Bone Graft Clinical Trial to Include University of Nebraska Medical Center
-- UNMC is 5th Site Open to Patient Enrollment for the Repair of Severe Leg Fractures Using Aastrom's Proprietary TRCs --
View HTML
Toggle Summary Aastrom Biosciences, Inc. Added to Russell 3000 Index
Aastrom Biosciences, Inc. Added to Russell 3000 Index Ann Arbor, Michigan, June 28, 2005 - Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that it was added to the Russell 3000® Index effective at the close of market on Friday, June 24, 2005.
View HTML
Toggle Summary Timothy M. Mayleben Elected to Aastrom Biosciences' Board of Directors
Timothy M. Mayleben Elected to Aastrom Biosciences' Board of Directors Ann Arbor, Michigan, June 22, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that Timothy M. Mayleben has been elected to the Company's Board of Directors. Mr. Mayleben's election became effective June 20, 2005
View HTML
Toggle Summary Aastrom Biosciences Appoints New Chief Financial Officer
-- Appointment of Gerald D. Brennan, Jr., JD, Effective July 2, 2005 --
View HTML
Toggle Summary Aastrom Biosciences' CEO to Present at the Morgan Stanley Small Cap Executive Conference
Aastrom Biosciences' CEO to Present at the Morgan Stanley Small Cap Executive Conference Ann Arbor, Michigan, June 10, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman, will present at the Morgan Stanley Small
View HTML
Toggle Summary Aastrom Biosciences Reports Positive Bone Repair Results in Clinical Feasibility Trial
-- Results Indicate Company's Tissue Repair Cell Product Achieves Local Bone Generation for Bone Grafting --
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports Third Quarter Fiscal Year 2005 Financial Results
Aastrom Biosciences, Inc. Reports Third Quarter Fiscal Year 2005 Financial Results Ann Arbor, Michigan, May 6 , 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today reported financial results for the third fiscal quarter ended March 31, 2005.  The Company also reported several achievements of the
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call Tomorrow
Aastrom Biosciences to Hold Investor Conference Call Tomorrow Ann Arbor, Michigan, May 5, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that it will host an investor conference call tomorrow, Friday, May 6, 2005 at 11:00 a.m. (ET). Interested parties should call (785) 832-0326,
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call
Aastrom Biosciences to Hold Investor Conference Call Ann Arbor, Michigan, May 3, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that it will host an investor conference call on Friday, May 6, 2005 at 11:00 a.m. (ET). Aastrom's call will begin with brief presentations by R.
View HTML
Toggle Summary Aastrom Biosciences' CEO to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference
Aastrom Biosciences' CEO to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference Ann Arbor, Michigan, April 29, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman, will present at the Rodman
View HTML
Toggle Summary Aastrom Biosciences Issues Statement on Unique Features of Its Bone Marrow Tissue Repair Cell Product and Technology
-- The Following is a Statement from R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman of Aastrom Biosciences, Inc. Regarding Recent Article in New Scientist Magazine --
View HTML
Toggle Summary Aastrom Biosciences Expands Bone Graft Clinical Trial to Include Lutheran Medical Center in Brooklyn, NY
-- Enrollment Open for Repair of Severe Leg Fractures Using Company's Proprietary TRCs at 4th Site --
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports Second Quarter Fiscal Year 2005 Financial Results
Aastrom Biosciences, Inc. Reports Second Quarter Fiscal Year 2005 Financial Results Ann Arbor, Michigan, February 4 , 2005 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today reported financial results for the second fiscal quarter ended December 31, 2004.  The Company also reported several
View HTML
Toggle Summary Warren Chaunce Bogard, Jr., Ph.D. Appointed to Aastrom Biosciences' Board of Directors
Warren Chaunce Bogard, Jr., Ph.D. Appointed to Aastrom Biosciences' Board of Directors Ann Arbor, Michigan, February 4, 2005 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that Warren Chaunce Bogard, Jr., Ph.D. has been appointed to the Company's Board of Directors.
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call Tomorrow
Aastrom Biosciences to Hold Investor Conference Call Tomorrow Ann Arbor, Michigan, February 3, 2005 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will host an investor conference call tomorrow, Friday, February 4, 2005 at 11:00 a.m. (EST).
View HTML
Toggle Summary Aastrom Biosciences Achieves Clinical Milestone in Its Phase I/II U.S. Bone Grafting Trial
-- Safety Endpoint for TRC Product Reached; Trial Expanded --
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call
Aastrom Biosciences to Hold Investor Conference Call Ann Arbor, Michigan, January 31, 2005 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will host an investor conference call on Friday, February 4, 2005 at 11:00 a.m. (EST). Aastrom's call will begin with brief presentations
View HTML
Toggle Summary Aastrom Biosciences Responds to Recent Article Regarding Contamination of Certain Stem Cell Lines
-- Aastrom Stem Cell Product's Progress on Clinical Pathway Not Impacted --
View HTML
Toggle Summary Aastrom Biosciences Receives Patent Expanding Coverage for Its Single-Pass Perfusion Technology
-- Patent Extends Coverage from Stem Cell Population to Dendritic Cells --
View HTML
Toggle Summary Aastrom Biosciences Concludes October 2002 Common Stock Agreement with Fusion Capital
-- Final $12 Million Tranche Completed at Premium to Market --
View HTML
Toggle Summary Aastrom Biosciences Expands Bone Graft Clinical Trial to Include William Beaumont Hospital in Michigan
-- Enrollment Open for Repair of Severe Leg Fractures Using Company's Proprietary TRCs --
View HTML
Toggle Summary Aastrom Biosciences Announces Appointment of Dr. Gunter Rosskamp as Managing Director of German Subsidiary
Aastrom Biosciences Announces Appointment of Dr. Gunter Rosskamp as Managing Director of German Subsidiary Ann Arbor, Michigan, and Berlin, Germany, December 9, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) and Zellera AG (Zellera), its wholly-owned subsidiary, today announced that Gunter
View HTML
Toggle Summary Aastrom Biosciences Issues Correction of Wall Street Journal Article
-- Adult Bone Marrow Stem Cells are Company Focus --
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports First Quarter Fiscal Year 2005 Financial Results
Aastrom Biosciences, Inc. Reports First Quarter Fiscal Year 2005 Financial Results Ann Arbor, Michigan, November 4 , 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today reported financial results for the first fiscal quarter ended September 30, 2004.  The Company also reported several
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call Tomorrow
Aastrom Biosciences to Hold Investor Conference Call Tomorrow Ann Arbor, Michigan, November 3, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will host an investor conference call tomorrow, Thursday, November 4, 2004 at 11:00 a.m. (EST).
View HTML
Toggle Summary Webcast Alert: Aastrom Biosciences, Inc. Presentation At Informed Investors
Biotechnology/Cancer Stocks Virtual Forum To Be Webcast On Thursday, November 4, 2004, 9:30am ET
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call
Aastrom Biosciences to Hold Investor Conference Call Ann Arbor, Michigan, November 1, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will host an investor conference call on Thursday, November 4, 2004 at 11:00 a.m. (EST). The call will begin with brief presentations by
View HTML
Toggle Summary Aastrom Biosciences Announces Diabetic Limb Ischemia Clinical Trial Agreement
-- Aastrom's Proprietary TRCs to be Used in Treatment of Limb Ischemia at the Bad Oeynhausen Heart and Diabetes Center in Germany --
View HTML
Toggle Summary Aastrom Biosciences Raises $10 Million in Equity Financing
Aastrom Biosciences Raises $10 Million in Equity Financing Ann Arbor, Michigan, October 27, 2004 - Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it has executed definitive Stock Purchase Agreements for the sale of approximately 8.26 million shares of the Company's common stock in
View HTML
Toggle Summary Aastrom Biosciences CEO to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference
Aastrom Biosciences CEO to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference Ann Arbor, Michigan, October 25, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today R. Douglas Armstrong, Ph.D., Chairman and Chief Executive Officer, will present at the Rodman &
View HTML
Toggle Summary Aastrom Biosciences Announces Initiation of Clinical Trial for Sinus Lift Bone Graft Procedures in Spain
-- Aastrom's Proprietary TRCs to be Utilized to Build New Bone Tissue for Dental Implants --
View HTML
Toggle Summary Aastrom Biosciences Announces Initiation of Clinical Trial for Sinus Lift Bone Graft Procedures in Spain
-- Aastrom's Proprietary TRCs to be Utilized to Build New Bone Tissue for Dental Implants --
View HTML
Toggle Summary Aastrom Biosciences Announces Plans to Expand Bone Graft Study Based on Results of Severe Fracture Treatments
Aastrom Biosciences Announces Plans to Expand Bone Graft Study Based on Results of Severe Fracture Treatments Ann Arbor, Michigan, October 18, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) and the Institut de Terapia Regenerativa Tissular (ITRT) announced today that their clinical trial in
View HTML
Toggle Summary Aastrom Awarded NIH Grant for Study to Enhance Dendritic Cell-Based Cancer Vaccines Utilizing the AastromReplicell
-- Aastrom's Proprietary Technology Provides Method of Cell Production and Antigen Loading Needed to Improve Vaccines --
View HTML
Toggle Summary Aastrom Biosciences Announces Appointment of Janet M. Hock, B.D.S., Ph.D. As Vice President Global Research
Aastrom Biosciences Announces Appointment of Janet M. Hock, B.D.S., Ph.D. As Vice President Global Research Ann Arbor, Michigan, September 14, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced the appointment of Janet M. Hock, B.D.S., Ph.D. as Vice President Global Research. Dr.
View HTML
Toggle Summary Aastrom Biosciences' CEO to Present at Roth Capital Partners New York Conference
Aastrom Biosciences' CEO to Present at Roth Capital Partners New York Conference Ann Arbor, Michigan, September 9, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman, will present at the Roth Capital Partners New
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports Fourth Quarter 2004 Financial Results
Aastrom Biosciences, Inc. Reports Fourth Quarter 2004 Financial Results Ann Arbor, Michigan, September 8, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today reported financial results for the fourth quarter and fiscal year ended June 30, 2004.  The Company also reported significant
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call
Aastrom Biosciences to Hold Investor Conference Call Ann Arbor, Michigan, September 7, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that it will hold an investor conference call on Wednesday, September 8, 2004 at 11:00 a.m. (EDT).
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call Tomorrow
Aastrom Biosciences to Hold Investor Conference Call Tomorrow Ann Arbor, Michigan, September 7, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that it will hold an investor conference call tomorrow, Wednesday, September 8, 2004 at 11:00 a.m. (EDT).
View HTML
Toggle Summary Aastrom Biosciences Appoints James A. Cour as President and COO
Aastrom Biosciences Appoints James A. Cour as President and COO Ann Arbor, Michigan, July 6, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today the appointment of James A. Cour as President and Chief Operating Officer. Mr. Cour will be responsible for the day-to-day operations of
View HTML
Toggle Summary Aastrom Biosciences Expands Bone Graft Clinical Trial to Include University of Michigan
-- Enrollment Open for Repair of Severe Leg Fractures at Orthopedic Trauma Center Using Company's Adult Stem Cell Product --
View HTML
Toggle Summary Aastrom Biosciences' CEO to Present at Rodman & Renshaw Techvest Global Healthcare Conference
Aastrom Biosciences' CEO to Present at Rodman & Renshaw Techvest Global Healthcare Conference Ann Arbor, Michigan, May 6, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that R. Douglas Armstrong, Ph.D., Chairman, President and Chief Executive Officer, will present at the Rodman
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports Third Quarter Fiscal Year 2004 Financial Results
Aastrom Biosciences, Inc. Reports Third Quarter Fiscal Year 2004 Financial Results Ann Arbor, Michigan, April 29, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM), today reported financial results for the third quarter of fiscal year 2004 ended March 31, 2004.
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call Tomorrow
Aastrom Biosciences to Hold Investor Conference Call Tomorrow Ann Arbor, Michigan, April 28, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will hold an investor conference call tomorrow, Thursday, April 29, 2004 at 11:00 a.m. (EDT).
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call
Aastrom Biosciences to Hold Investor Conference Call Ann Arbor, Michigan, April 27, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that it will hold an investor conference call on Thursday, April 29, 2004 at 11:00 a.m. (EDT). The purpose of the call will be to bring shareholders
View HTML
Toggle Summary Aastrom Biosciences Awarded NIH Grant to Develop Immunotherapy for the Treatment of Malignant Melanoma
-- Aastrom's Proprietary Technology Used to Produce Therapeutic Quantities of T-Cells --
View HTML
Toggle Summary Aastrom Biosciences Corrects Warrant Exercise Price Related to April 5, 2004 Sale of Common Stock
Aastrom Biosciences Corrects Warrant Exercise Price Related to April 5, 2004 Sale of Common Stock Ann Arbor, Michigan, April 6, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that the exercise price of the warrants issued to a group of institutional investors was $1.65 per share
View HTML
Toggle Summary Aastrom Biosciences Announces $9.1 Million Private Placement of Common Stock
Aastrom Biosciences Announces $9.1 Million Private Placement of Common Stock Ann Arbor, Michigan, April 5, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it has placed 8 million shares of common stock with institutional investors at approximately $1.14 per share, for an
View HTML
Toggle Summary Aastrom Biosciences Announces the Initiation of a Clinical Trial for Bone Grafting in Spain
-- Aastrom's Proprietary TRCs to be Utilized in Second European Clinical Study to Treat Major Bone Fractures --
View HTML
Toggle Summary Aastrom Biosciences Further Facilitates Process for Participation in Direct Stock Purchase Program
-- New Form Simplifies Enrollment for Shareholders with Shares in "Street Name" --
View HTML
Toggle Summary Aastrom Biosciences Receives Patent for Transplantation Use of Its Stem Cell Products
-- Patent Covers Bone Marrow, Blood and Cord Blood-Sourced Products --
View HTML
Toggle Summary Aastrom Biosciences' CEO to Present at Roth Capital Partners 16th Annual Growth Stock Conference
Aastrom Biosciences' CEO to Present at Roth Capital Partners 16th Annual Growth Stock Conference Ann Arbor, Michigan, February 12, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that R. Douglas Armstrong, Ph.D., Chairman, President and Chief Executive Officer, has been invited
View HTML
Toggle Summary Linda Manoogian Fingerle Appointed to Aastrom Biosciences' Board of Directors
Linda Manoogian Fingerle Appointed to Aastrom Biosciences' Board of Directors Ann Arbor, Michigan, February 5, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that Linda Manoogian Fingerle was appointed to the Company's Board of Directors. Ms.
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports Second Quarter Fiscal Year 2004 Financial Results
Aastrom Biosciences, Inc. Reports Second Quarter Fiscal Year 2004 Financial Results Ann Arbor, Michigan, February 4, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM), today reported financial results for the second quarter of fiscal year 2004 ended December 31, 2003.
View HTML
Toggle Summary astrom Biosciences to Hold Investor Conference Call Tomorrow
astrom Biosciences to Hold Investor Conference Call Tomorrow Ann Arbor, Michigan, February 3, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will hold an investor conference call tomorrow, Wednesday, February 4, 2004 at 11:00 a.m. EST.
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call
Aastrom Biosciences to Hold Investor Conference Call Ann Arbor, Michigan, January 30, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will hold an investor conference call on Wednesday, February 4, 2004 at 11:00 a.m. EST. The call is intended to bring shareholders and
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call
Aastrom Biosciences to Hold Investor Conference Call Ann Arbor, Michigan, January 30, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will hold an investor conference call on Wednesday, February 4, 2004 at 11:00 a.m. EST. The call is intended to bring shareholders and
View HTML
Toggle Summary Aastrom Biosciences Announces Initiation of Bone Graft Clinical Study in Germany
Bergmannsheil University Begins Patient Enrollment for New Stem Cell Treatment of Severe Leg Fractures
View HTML
Toggle Summary Aastrom Biosciences Announces Initiation of Bone Graft Clinical Study in Germany
-- Bergmannsheil University Begins Patient Enrollment for New Stem Cell Treatment of Severe Leg Fractures --
View HTML
Toggle Summary Aastrom Biosciences Initiates Bone Graft Clinical Trial at Lead U.S. Site
Evaluation of Stem Cell Product for Leg Fracture Healing Begins in Chicago
View HTML
Toggle Summary Aastrom Biosciences Initiates Bone Graft Clinical Trial at Lead U.S. Site
-- Evaluation of Stem Cell Product for Leg Fracture Healing Begins in Chicago --
View HTML
Toggle Summary Aastrom's Dendritic Cell Vaccine Technology to be Utilized in Duke University's Clinical Trial for New Cancer Treatment
-- Duke Clinical Trial Seeks New Treatment for GI Tract Cancers --
View HTML
Toggle Summary Aastrom Biosciences Holds Investor Conference Call Today
Aastrom Biosciences Holds Investor Conference Call Today Ann Arbor, Michigan, November 14, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) will hold an investor call today, November 14, 2003 at 10:00 a.m. EST. The purpose of the call is to bring shareholders and other interested parties
View HTML